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A B S T R A C T
Background
Acute otitis media (AOM) is one of the most common diseases in early infancy and childhood. Antibiotic use for AOM varies from
56% in the Netherlands to 95% in the USA, Canada and Australia. This is an update of a Cochrane review first published in The
Cochrane Library in Issue 1, 1997 and previously updated in 1999, 2005, 2009 and 2013.
Objectives
To assess the effects of antibiotics for children with AOM.
Search methods
We searched CENTRAL (2015, Issue 3), MEDLINE (1966 to April week 3, 2015), OLDMEDLINE (1958 to 1965), EMBASE
(January 1990 to April 2015), Current Contents (1966 to April 2015), CINAHL (2008 to April 2015) and LILACS (2008 to April
2015).
Selection criteria
Randomised controlled trials (RCTs) comparing 1) antimicrobial drugs with placebo and 2) immediate antibiotic treatment with
expectant observation (including delayed antibiotic prescribing) in children with AOM.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data.
Main results
For the review of antibiotics against placebo, 13 RCTs (3401 children and 3938 AOM episodes) from high-income countries were
eligible and had generally low risk of bias. The combined results of the trials revealed that by 24 hours from the start of treatment, 60%
of the children had recovered whether or not they had placebo or antibiotics. Pain was not reduced by antibiotics at 24 hours (risk
ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01) but almost a third fewer had residual pain at two to three days (RR 0.70,
95% CI 0.57 to 0.86; number needed to treat for an additional beneficial outcome (NNTB) 20). A quarter fewer had pain at four to
seven days (RR 0.76, 95% CI 0.63 to 0.91; NNTB 16) and two-thirds fewer had pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to
0.66; NNTB 7) compared with placebo. Antibiotics did reduce the number of children with abnormal tympanometry findings at two
to four weeks (RR 0.82, 95% CI 0.74 to 0.90; NNTB 11), at six to eight weeks (RR 0.88, 95% CI 0.78 to 1.00; NNTB 16) and the
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number of children with tympanic membrane perforations (RR 0.37, 95% CI 0.18 to 0.76; NNTB 33) and halved contralateral otitis
episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11) compared with placebo. However, antibiotics neither reduced the number of
children with abnormal tympanometry findings at three months (RR 0.97, 95% CI 0.76 to 1.24) nor the number of children with late
AOM recurrences (RR 0.93, 95% CI 0.78 to 1.10) when compared with placebo. Severe complications were rare and did not differ
between children treated with antibiotics and those treated with placebo. Adverse events (such as vomiting, diarrhoea or rash) occurred
more often in children taking antibiotics (RR 1.38, 95% CI 1.19 to 1.59; number needed to treat for an additional harmful outcome
(NNTH) 14). Funnel plots do not suggest publication bias. Individual patient data meta-analysis of a subset of included trials found
antibiotics to be most beneficial in children aged less than two years with bilateral AOM, or with both AOM and otorrhoea.
For the review of immediate antibiotics against expectant observation, five trials (1149 children) from high-income countries were
eligible and had low to moderate risk of bias. Four trials (1007 children) reported outcome data that could be used for this review.
From these trials, data from 959 children could be extracted for the meta-analysis of pain at three to seven days. No difference in pain
was detectable at three to seven days (RR 0.75, 95% CI 0.50 to 1.12). One trial (247 children) reported data on pain at 11 to 14
days. Immediate antibiotics were not associated with a reduction in the number of children with pain (RR 0.91, 95% CI 0.75 to 1.10)
compared with expectant observation. Additionally, no differences in the number of children with abnormal tympanometry findings at
four weeks, tympanic membrane perforations and AOM recurrence were observed between groups. No serious complications occurred
in either the antibiotic or the expectant observation group. Immediate antibiotics were associated with a substantial increased risk of
vomiting, diarrhoea or rash compared with expectant observation (RR 1.71, 95% CI 1.24 to 2.36; NNTH 9).
Results from an individual patient data meta-analysis including data from six high-quality trials (1643 children) that were also included
as individual trials in our review showed that antibiotics seem to be most beneficial in children younger than two years of age with
bilateral AOM (NNTB 4) and in children with both AOM and otorrhoea (NNTB 3).
Authors’ conclusions
This review reveals that antibiotics have no early effect on pain, a slight effect on pain in the days following and only a modest effect
on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to
four weeks and at six to eight weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM
spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children
treated with antibiotics one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if
antibiotics were withheld. Therefore clinical management should emphasise advice about adequate analgesia and the limited role for
antibiotics. Antibiotics are most useful in children under two years of age with bilateral AOM, or with both AOM and otorrhoea. For
most other children with mild disease in high-income countries, an expectant observational approach seems justified.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for acute middle ear infection (acute otitis media) in children
Review questions
This review compared 1) the clinical effectiveness and safety of antibiotics against placebo in children with an acute middle ear infection
(acute otitis media (AOM)) and 2) the clinical effectiveness and safety of antibiotics against expectant observation (observational
approaches in which prescriptions may or may not be provided) in children with AOM.
Background
AOM is one of the most common infections in early infancy and childhood, causing pain and general symptoms of illness such as
fever, irritability and problems feeding and sleeping. By three years of age, most children have had at least one AOM episode. Though
AOM usually resolves without treatment, it is often treated with antibiotics.
Study characteristics
The evidence in this review is current to 26 April 2015.
For the review of antibiotics against placebo we included 13 trials (3401 children aged between two months and 15 years) from high-
income countries with generally low risk of bias. Three trials were performed in a general practice (GP) setting, six in an outpatient
hospital setting and four in both settings.
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For the review of antibiotics against expectant observation, five trials (1149 children) from high-income countries were eligible with
low to moderate risk of bias. Two trials were performed in a GP setting and three in an outpatient hospital setting. Four trials (1007
children) reported outcome data that could be used for this review.
Key results
We found that antibiotics were not very useful for most children with AOM; antibiotics did not decrease the number of children with
pain at 24 hours (when 60% of children were better anyway), only slightly reduced the number of children with pain in the days
following and did not reduce the number of children with late AOM recurrences and hearing loss (that can last several weeks) at three
months compared with placebo. However, antibiotics did slightly reduce the number of children with perforations of the eardrum and
AOM episodes in the initially unaffected ear compared with placebo. Results from an individual patient data meta-analysis including
data from six high-quality trials (1643 children), which were also included as individual trials in our review, showed that antibiotics
seem to be most beneficial in children younger than two years of age with infection in both ears and in children with both AOM and
a discharging ear.
We found no difference between immediate antibiotics and expectant observational approaches in the number of children with pain
three to seven days and 11 to 14 days after assessment. Furthermore, no differences in the number of children with hearing loss at four
weeks, perforations of the eardrum and late AOM recurrences were observed between groups.
There was not enough information to know if antibiotics reduced rare complications such as mastoiditis (infection of the bones around
the ear). All of the studies included in this review were from high-income countries. Data are lacking from populations in which the
AOM incidence and risk of progression to mastoiditis is higher.
Antibiotics caused unwanted effects such as diarrhoea, vomiting and rash andmay also increase resistance to antibiotics in the community.
It is difficult to balance the small benefits against the small harms of antibiotics in children with AOM. However, for most children
with mild disease in high-income countries, an expectant observational approach seems justified.
Quality of the evidence
We judged the quality of the evidence to be high for most of the outcomes in the review of antibiotics against placebo (this means that
further research is very unlikely to change our confidence in the estimate of effect).
For the review of immediate antibiotics versus expectant observation, we judged the evidence to be of moderate quality for most of
the outcomes (this means that further research is likely to have an important impact on how confident we are in the results and may
change those results). Quality was affected by concerns about sample size (perforation of the eardrum, rare complications) and the large
number of children who are ’lost to follow-up’ (pain at days 11 to 14, hearing loss at four weeks and late AOM recurrences).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics versus placebo for acute otitis media in children
Patient or population: children with acute ot it is media
Settings: primary care and secondary care
Intervention: ant ibiot ics versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antibiotics versus
placebo
Pain - pain at 24 hours Study population RR 0.89
(0.78 to 1.01)
1394
(5 studies)1
⊕⊕⊕⊕
high
426 per 1000 379 per 1000
(332 to 431)
Pain - pain at 2 to 3
days
Study population RR 0.70
(0.57 to 0.86)
2320
(7 studies)
⊕⊕⊕⊕
high
159 per 1000 111 per 1000
(90 to 137)
Pain - pain at 4 to 7
days
Study population RR 0.76
(0.63 to 0.91)
1347
(7 studies)1
⊕⊕⊕⊕
high
241 per 1000 183 per 1000
(152 to 220)
Pain - pain at 10 to 12
days
Study population RR 0.33
(0.17 to 0.66)
278
(1 study)
⊕⊕⊕©
moderate2
216 per 1000 71 per 1000
(37 to 142)
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Abnormal tympanome-
try - 2 to 4 weeks
Study population RR 0.82
(0.74 to 0.90)
2138
(7 studies)
⊕⊕⊕⊕
high
481 per 1000 395 per 1000
(356 to 433)
Abnormal tympanome-
try - 3 months
Study population RR 0.97
(0.76 to 1.24)
809
(3 studies)
⊕⊕⊕⊕
high
241 per 1000 234 per 1000
(183 to 299)
Vomiting, diarrhoea or
rash
Study population RR 1.38
(1.19 to 1.59)
2107
(8 studies)
⊕⊕⊕⊕
high
196 per 1000 270 per 1000
(233 to 311)
* The basis for the assumed risk f or ‘Study populat ion’ was the average risk in the control groups (i.e. total number of part icipants with events divided by total number of
part icipants included in the meta-analysis). The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1The number of studies reported in the ’Summary of f indings’ table for the outcomes ’Pain at 24 hours’ and ’Pain at 4 to 7
days’ dif f er slight ly f rom those reported in the Data Analysis Table 1 - Ant ibiot ics versus placebo (f ive versus six studies
and seven versus eight studies, respect ively). This is due to the van Buchem trial. This trial is included as one study in
our review (and in the ’Summary of f indings’ table), but we included data f rom two dif ferent comparisons f rom this 2 x 2
factorial design trial in our analyses (van Buchem 1981a; van Buchem 1981b).
2We downgraded the evidence for pain at days 10 to 12 f rom high quality as this outcome was not specif ied a priori in this
trial (secondary analysis).
5
A
n
tib
io
tic
s
fo
r
a
c
u
te
o
titis
m
e
d
ia
in
c
h
ild
re
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is one of the most frequent diseases
in early infancy and childhood. AOM is defined as the presence
of middle-ear effusion and a rapid onset of signs or symptoms
of middle-ear inflammation, such as ear pain, otorrhoea or fever
(AAP 2013), and has a high morbidity and low mortality (Stool
1989). Approximately 10% of children have an episode of AOM
by three months of age and, by three years of age, approximately
50% to 85% of all children have experienced at least one AOM
episode (Teele 1989). The peak age-specific incidence is between
six and 15 months (Klein 1989).
Description of the intervention
Despite a large number of published clinical trials, there is no
consensus regarding the most appropriate therapy for AOM; for
example, the rates of use of antibiotics for AOM vary from 56%
in the Netherlands (Akkerman 2005) to 95% in the USA and
Canada (Froom 2001). One meta-analysis emphasises that AOM
resolves spontaneously in most children (Rosenfeld 1994). How-
ever, one semi-randomised trial of 1365 participants conducted
in Sweden in 1954 reported a rate of mastoiditis of 17% in
the untreated group versus none in the penicillin-treated groups
(Rudberg 1954). Over recent years, prescription strategies in
which antibiotic treatment for acute respiratory infections such as
AOM is delayed and instituted only if symptoms persist or worsen
after several days have been advocated (AAP 2013).
How the intervention might work
AOM has a multifactorial pathogenesis. Mucosal swelling of the
nasopharynx and Eustachian tube due to a viral upper respiratory
tract infection can lead to Eustachian tube dysfunction with im-
paired clearance and pressure regulation of the middle ear. Pro-
longeddysfunctionmay be followedby aspiration of potential viral
and bacterial pathogens from the nasopharynx to the middle ear.
These pathogens might in turn provoke a host inflammatory re-
sponse, which leads to the clinical manifestations of AOM such as
ear pain, otorrhoea, fever and irritability. Streptococcus pneumoniae
(S. pneumoniae) has been the predominant pathogen related to
AOM formany years, next toMoraxella catarrhalis (M. catarrhalis)
and non-typeable Haemophilus influenzae (H. influenzae). How-
ever, recent studies suggest that widespread implementation of
pneumococcal conjugate vaccination has changed the frequency
of otopathogens related to AOM with non-typeable H. influenzae
and non-vaccine S. pneumoniae serotypes becoming more preva-
lent (Casey 2013; Coker 2010). Additionally, viral (co-)infection
is known to worsen the clinical and bacteriological outcome of
AOM (Arola 1990; Chonmaitree 1992). As bacteria are consid-
ered to play a predominant role in the causation of AOM-related
symptoms, antibiotic treatment may accelerate clinical recovery
and may reduce the number of complications related to AOM.
Why it is important to do this review
Althoughnumerous randomised clinical trials (RCTs) on the effec-
tiveness of antibiotic treatment in children with AOM have been
performed over the decades, consensus regarding the most appro-
priate treatment strategy is lacking. As symptoms consistent with
AOM resolve spontaneously in the majority of children, an expec-
tant observational approach might be justified. We therefore per-
formed a systematic review to examine the effects of both immedi-
ate antibiotic treatment and an expectant observational approach
in children with AOM. This is an update of a Cochrane review
first published in The Cochrane Library in Issue 1, 1997 (Glasziou
1997) and updated in 1999 (Glasziou 1999), 2005 (Glasziou
2005), 2009 (Sanders 2009), and 2013 (Venekamp 2013).
O B J E C T I V E S
To assess the effects of antibiotics for children with AOM.
We attempted to determine to what extent antibiotic therapy was
more effective than placebo and what, if any, advantages it offered
to children in terms of symptom relief (pain), avoidance of com-
plications (such as tympanic membrane perforations and severe
complications such as mastoiditis) and longer-term hearing prob-
lems from middle-ear effusion (as measured by tympanometry or
audiometry). We also assessed the effect of immediate antibiotic
versus expectant observation on AOM. Moreover, we aimed to
provide information on subgroups of children with AOM that
benefit more or less from antibiotics.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs of antimicrobial drugs versus placebo control. We also in-
cluded RCTs comparing immediate antibiotic versus expectant
observation.
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Types of participants
Studies including children (aged from one month to 15 years)
of either gender without ventilation tubes, suffering from AOM
irrespective of the setting from which they were recruited.
Types of interventions
Antimicrobial drugs versus placebo control.
Immediate antibiotic versus expectant observation (also known
as ’wait and see’ or ’watchful waiting’ or ’observation therapy’).
This includes expectant observational approaches in which pre-
scriptions may or may not be provided.
Types of outcome measures
We focused our data extraction on patient-relevant outcomes, that
is, those symptoms or problems that are important to the patient’s
sense of well-being. While other endpoints, such as microbiolog-
ical cure, may enhance medical understanding of the disease pro-
cess, decisions about treatment should focus on helping the pa-
tient. We analysed the outcomes listed below in this review, but
these outcomes were not used as a basis for including or excluding
studies.
Primary outcomes
1. Proportion of children with pain at various time points (24
hours, two to three days, four to seven days, 10 to 14 days).
2. Adverse effects likely to be related to the use of antibiotics
such as vomiting, diarrhoea or rash.
Secondary outcomes
1. Abnormal tympanometry findings at various time points
(two to four weeks, six to eight weeks, and three months) as a
surrogate measure for hearing problems caused by middle-ear
fluid.
2. Tympanic membrane perforation.
3. Contralateral otitis (in unilateral cases).
4. AOM recurrences.
5. Serious complications related to AOM such as mastoiditis
and meningitis.
6. Long-term effects (including the number of parent-reported
AOM-symptom episodes, antibiotic prescriptions and health
care utilisation as assessed at least one year after randomisation).
Search methods for identification of studies
Electronic searches
For this update we searched theCochraneCentral Register of Con-
trolledTrials (CENTRAL 2015, Issue 3) (accessed 26 April 2015),
which contains the Acute Respiratory Infections (ARI) Group’s
Specialised Register, MEDLINE (October 2012 to April week 3,
2015), EMBASE (November 2012 to April 2015), Current Con-
tents (2012 to April 2015), CINAHL (October 2012 to April
2015) and LILACS (2012 to April 2015). Our previous update us-
ing the same search strategies covered the period 2008 to Novem-
ber 2012. See Appendix 1 for details of earlier searches.
We used the search strategy described in Appendix 2 to search
CENTRALandMEDLINE.We combined theMEDLINEsearch
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision);Ovid format (Lefebvre 2011).
We adapted the search strategy to search EMBASE (Appendix
3), Current Contents (Appendix 4), CINAHL (Appendix 5) and
LILACS (Appendix 6).
There were no language or publication restrictions.
Searching other resources
We checked ClinicalTrials.gov (clinicaltrials.gov/) for ongoing tri-
als (11 May 2015). To increase the yield of relevant studies, we
inspected the reference lists of all identified studies and reviews.
Data collection and analysis
Selection of studies
One review author (RPV) screened titles and abstracts obtained
from the database searches. Two review authors (RPV, MMR)
reviewed the full text of the potentially relevant titles and abstracts
against the inclusion criteria.
Data extraction and management
Two review authors (RPV,MMR) extracted data from the included
studies. We resolved disagreements by discussion.
Assessment of risk of bias in included studies
Two review authors (RPV, MMR) independently assessed the
methodological quality of the included trials. We resolved any dis-
agreements by discussion. We assessed the methodological quality
of the included studies as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). As a conse-
quence, methodological quality assessment was based on random
sequence generation, allocation concealment, blinding, complete-
ness of data and outcome assessment. Results of the ’Risk of bias’
assessment are presented in a ’Risk of bias’ summary (Figure 1)
and a ’Risk of bias’ graph (Figure 2).
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Measures of treatment effect
We expressed dichotomous outcomes as risk ratio (RR) and risk
difference (RD) with 95% confidence intervals (CIs). Addition-
ally, we calculated the number needed to treat for an additional
beneficial outcome (NNTB) and the number needed to treat for
an additional harmful outcome (NNTH) (1/(absolute risk in ex-
posed minus absolute risk in unexposed)).
Unit of analysis issues
We did not identify any studies with non-standard designs, such
as cross-over trials and cluster-randomised trials.
Dealing with missing data
We tried to contact the trial authors to provide additional infor-
mation in case of missing data.
Assessment of heterogeneity
We assessed the level of clinical heterogeneity between the trials
by reviewing differences across trials in study population, setting,
intervention and outcome measures used. In the absence of sub-
stantial clinical heterogeneity, we performed meta-analyses. We
used the Chi2 test, the I2 statistic and visual inspection of the for-
est plots to assess statistical heterogeneity.When statistical hetero-
geneity was present (P value < 0.1), we re-analysed the data using
the random-effects model. For the outcome of pain, we explored
the magnitude of baseline risk and heterogeneity using L’Abbé
plots (a graph of the proportion of participants with an outcome
by the proportion of participants without an outcome).
Assessment of reporting biases
We assessed reporting bias using a funnel plot.
Data synthesis
We analysed the data according to the intention-to-treat (ITT)
principle, whereby all participants are analysed in the groups to
which they were randomly allocated. We performed meta-analy-
sis where we judged clinical heterogeneity to be minimal, to en-
sure that we would derive clinically meaningful results. We calcu-
lated treatment differences by the Mantel-Haenszel method using
a fixed-effect or random-effects (when statistical heterogeneity was
present) model. We presented results separately for the reviews of
antibiotics against placebo and immediate antibiotics versus ex-
pectant observation.
Subgroup analysis and investigation of heterogeneity
The publication of Rovers 2006 describes the results of an individ-
ual patient data (IPD) meta-analysis that was performed on a sub-
set of trials included in this review (six trials including 1643 chil-
dren aged sixmonths to 12 years with AOM) to identify subgroups
of children with AOM who might benefit more than others from
treatment with antibiotics. Extensive details on the methods and
results of this IPD meta-analysis can be found in the original arti-
cle (Rovers 2006). The primary outcome was a prolonged course
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of AOM defined as having either residual pain or fever (> 38 ºC)
at three to seven days. Potential subgroups were selected on the
basis of a multivariable prediction tool. The independent baseline
predictors, that is, age (< two years versus > two years), fever and
bilateral AOM (yes versus no), were used to study whether those
at risk of a prolonged course also benefited more from treatment
with antibiotics. In addition, otorrhoea (yes versus no) at baseline
was studied as this is a clinically relevant outcome that occurred
too infrequently to be identified as an independent predictor. To
assess whether the effect of antibiotics was modified by age, bi-
lateral disease, otorrhoea or a combination of these, a fixed-effect
logistic regression analysis. In this model, antibiotics (yes versus
no), the potential effect modifier (age, bilateral disease, otorrhoea,
or a combination of these), a dummy for the particular study and
an interaction term (antibiotics * potential effect modifier) were
included as independent variables and a prolonged course at three
to seven days was the dependent variable. If a significant interac-
tion effect was found, stratified analyses were performed to study
the rate ratios and rate differences within each stratum of the sub-
groups.
Sensitivity analysis
We did not perform sensitivity analysis.
GRADE and ’Summary of findings’
For each outcome, we rated the overall quality of evidence as high,
moderate, low and very low using the GRADE approach. Ran-
domised controlled trials that do not have serious limitations are
rated as high quality. However, we downgraded the evidence to
moderate, low or very low depending on the presence of each of
the following factors:
• study limitations (risk of bias);
• indirectness of evidence (directness of evidence);
• imprecision (precision of results);
• inconsistency (consistency of results); and
• publication bias (existence of publication bias).
We included a ’Summary of findings’ table (Summary of findings
for the main comparison) for the review of antibiotics against
placebo, constructed according to the descriptions as described in
Chapter 10 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We included our primary outcomes
and important secondary outcomes in the ’Summary of findings’
table:
• pain at 24 hours;
• pain at two to three days;
• pain at four to seven days;
• pain at 10 to 12 days;
• adverse effects likely to be related to the use of antibiotics
(vomiting, diarrhoea or rash);
• abnormal tympanometry findings at two to four weeks;
• abnormal tympanometry findings at three months.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies and Characteristics of ongoing studies tables.
Results of the search
This is an update of a Cochrane review first published in The
Cochrane Library in Issue 1, 1997 (Glasziou 1997) and updated
in 1999 (Glasziou 1999), 2005 (Glasziou 2005), 2009 (Sanders
2009), and 2013 (Venekamp 2013). In the 2013 update of our
review (Venekamp 2013), we identified 12 RCTs for the re-
view of antibiotics against placebo (Appelman 1991; Burke 1991;
Damoiseaux 2000; Halsted 1968; Hoberman 2011; Howie 1972;
Kaleida 1991; Le Saux 2005; Mygind 1981; Tähtinen 2011;
Thalin 1985; van Buchem 1981a and van Buchem 1981b), while
we judged five RCTs eligible for the review of immediate an-
tibiotics versus expectant observation (Laxdal 1970; Little 2001;
McCormick 2005; Neumark 2007; Spiro 2006). We excluded a
total of 11 studies for various reasons (Arguedas 2011; Casey 2012;
Chaput 1982; Engelhard 1989; Liu 2011; Ostfeld 1987; Rudberg
1954; Ruohola 2003; Sarrell 2003; Tähtinen 2012; van Buchem
1985).
With the updated search (November week 2, 2012 to April week
3, 2015), we retrieved a total of 1065 records. Removing du-
plicates left 937. After screening titles and abstracts, we iden-
tified four potentially eligible articles. After reviewing the full
text, all articles appeared to be relevant for this review. However,
three articles were additional analyses of previously included tri-
als (Damoiseaux 2000; Hoberman 2011; Little 2001), providing
additional data on pain at 10 to 12 days (Hoberman 2011) and
long-term effects (Damoiseaux 2000) for the review of antibiotics
against placebo and data on long-term effects (Little 2001) for the
review of immediate antibiotics versus expectant observation. We
did not identify any additional trials after reviewing the reference
lists of the full-text papers and relevant systematic reviews. This
left one new trial eligible for inclusion in the review of antibiotics
against placebo (Tapiainen 2014). We identified one ongoing trial
(ACTRN12608000424303).
Included studies
Methods, participants, interventions and outcomes of the in-
cluded studies are described in more detail in the table of
Characteristics of included studies.
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Antibiotics versus placebo
Thirteen trials including 3401 children (3938 AOM episodes)
were eligible for the review of antibiotics against placebo (
Appelman 1991; Burke 1991; Damoiseaux 2000; Halsted 1968;
Hoberman 2011; Howie 1972; Kaleida 1991; Le Saux 2005;
Mygind 1981; Tähtinen 2011; Tapiainen 2014; Thalin 1985; van
Buchem 1981a and van Buchem 1981b).
Design
Twelve trials were double-blind, placebo-controlled, parallel-
group randomised clinical trials (Appelman 1991; Burke 1991;
Damoiseaux 2000; Halsted 1968; Hoberman 2011; Howie 1972;
Kaleida 1991; Le Saux 2005; Mygind 1981; Tähtinen 2011;
Tapiainen 2014; Thalin 1985), while one trial had a 2 x 2 factorial
design (van Buchem 1981a and van Buchem 1981b).
Participants and settings
The sample size of the 13 individual trials ranged from 84 chil-
dren (Tapiainen 2014) to 536 children (Kaleida 1991). The chil-
dren were aged between two months and 15 years and 50%
to 60% of included children were male. Three trials were per-
formed in primary care (Burke 1991;Damoiseaux 2000; Tähtinen
2011), six in secondary care (Halsted 1968; Hoberman 2011;
Howie 1972; Kaleida 1991; Le Saux 2005; Thalin 1985), and four
in both primary and secondary care (Appelman 1991; Mygind
1981; Tapiainen 2014; van Buchem 1981a and van Buchem
1981b). AOM was diagnosed by the presence of acute symp-
toms and otoscopic signs in nine trials (Appelman 1991; Burke
1991; Damoiseaux 2000; Halsted 1968; Hoberman 2011; Howie
1972; Kaleida 1991; Mygind 1981; van Buchem 1981a and van
Buchem 1981b), and by the presence of middle-ear effusion at
pneumatic otoscopy and/or tympanometry in three trials (Le Saux
2005; Tähtinen 2011; Tapiainen 2014), while the criteria were
not clearly described in one trial (Thalin 1985).
Interventions and comparators
Two trials compared penicillin for seven days with placebo
(Mygind 1981; Thalin 1985), four trials compared amoxicillin
for seven to 14 days with or without myringotomy with placebo
(Burke 1991; Damoiseaux 2000; Kaleida 1991; Le Saux 2005),
and four trials compared amoxicillin/clavulanate for seven to 10
days with placebo (Appelman 1991; Hoberman 2011; Tähtinen
2011; Tapiainen 2014). In one trial, ampicillin for 10 days
was compared with pheneticillin and sulfisoxazole and placebo
(Halsted 1968), while another trial compared erythromycin and
triple sulphonamide with ampicillin, triple sulphonamide, ery-
thromycin and placebo (Howie 1972). One trial, van Buchem
1981a and van Buchem 1981b, had a 2 x 2 factorial design result-
ing in four treatment groups: (1) sham myringotomy plus antibi-
otics; (2) sham myringotomy plus placebo; (3) myringotomy plus
antibiotics; and (4)myringotomy plus placebo.We used all arms of
this trial: van Buchem 1981a includes the shammyringotomy plus
antibiotic and the sham myringotomy plus placebo arms, whereas
van Buchem 1981b includes themyringotomy plus antibiotic and
myringotomy plus placebo arms.
Outcomes
Pain
Five trials (1394 children) reported data on pain at 24 hours (
Burke 1991; Le Saux 2005; Thalin 1985; Tähtinen 2011; van
Buchem 1981a and van Buchem 1981b), seven (2320 children)
on pain at two to three days (Appelman 1991; Halsted 1968;
Kaleida 1991; Le Saux 2005; Mygind 1981; Tähtinen 2011;
Thalin 1985), seven (1347 children) on pain at four to seven
days (Burke 1991; Damoiseaux 2000; Mygind 1981; Tähtinen
2011; Tapiainen 2014; Thalin 1985; van Buchem 1981a and van
Buchem 1981b), and one (278 children) on pain at 10 to 12 days
(Hoberman 2011).
Adverse effects likely to be related to the use of antibiotics
(vomiting, diarrhoea or rash)
Eight trials (2107 children) reported data on adverse events likely
to be related to the use of antibiotics such as vomiting, diarrhoea or
rash (Burke 1991; Damoiseaux 2000; Hoberman 2011; Le Saux
2005; Mygind 1981; Tähtinen 2011; Tapiainen 2014; Thalin
1985).
Abnormal tympanometry findings as a surrogate measure for
hearing problems
Seven trials (2138 children) reported data on abnormal tympa-
nometry findings at two to four weeks (Appelman 1991; Burke
1991; Kaleida 1991; Le Saux 2005; Mygind 1981; Tapiainen
2014; Thalin 1985), three (953 children) on abnormal tympa-
nometry findings at six to eight weeks (Damoiseaux 2000; Kaleida
1991; Tapiainen 2014), and three (809 children) on abnormal
tympanometry findings at three months (Burke 1991; Le Saux
2005;Mygind 1981), as a surrogate measure for hearing problems
caused by middle-ear fluid.
Tympanic membrane perforation
Five trials (1075 children) reported data on tympanic mem-
brane perforation (Burke 1991; Hoberman 2011; Mygind 1981;
Tähtinen 2011; Tapiainen 2014).
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Progression of symptoms (contralateral otitis or late AOM
recurrences)
Four trials (906 children) reported data on contralateral otitis (in
unilateral cases) (Burke 1991; Hoberman 2011; Mygind 1981;
Thalin 1985), while six trials (2200 children) reported data on
late AOM recurrences (Hoberman 2011; Kaleida 1991; Le Saux
2005; Mygind 1981; Thalin 1985; van Buchem 1981a).
Serious complications
Ten trials reported on serious complications including mastoidi-
tis or meningitis (Burke 1991; Damoiseaux 2000; Hoberman
2011; Howie 1972; Kaleida 1991; Le Saux 2005; Mygind 1981;
Tähtinen 2011; Tapiainen 2014; van Buchem 1981a and van
Buchem 1981b), while information on complications was not ex-
plicitly reported in three trials (Appelman 1991; Halsted 1968;
Thalin 1985).
Long-term effects
One trial reported data on secondary care referrals at one year after
randomisation as assessed by reviewing the children’s notes (Burke
1991). Four children in the antibiotic group (4%) and seven in
the placebo group (6%) were lost to follow-up.
One trial reported data on the proportion of children with AOM
recurrences, secondary care referrals and ENT surgery at approx-
imately 3.5 years after randomisation (Damoiseaux 2000). These
long-term outcome data were collected by questionnaires. Ques-
tionnaires were returned in 168 of the 240 children (70%) that
were originally randomised.
Immediate antibiotics versus expectant observation
Five trials including a total of 1149 children were eligible for the
review of immediate antibiotics versus expectant observation (
Laxdal 1970; Little 2001; McCormick 2005; Neumark 2007;
Spiro 2006).
Design
All trials were open-label, parallel-group randomised clinical trials.
Participants and settings
The sample size of the five individual trials ranged from 142 chil-
dren (Laxdal 1970) to 315 children (Little 2001). The children
were aged 15 years and younger and 50% to 60% of included chil-
dren were male. Two trials were performed in primary care (Little
2001; Neumark 2007), and three in secondary care (Laxdal 1970;
McCormick 2005; Spiro 2006). AOMwas diagnosed by the pres-
ence of acute symptoms and otoscopic signs in three trials (Laxdal
1970; Little 2001; McCormick 2005), by pneumatic otoscopy or
preferably an aural microscope in one trial (Neumark 2007), while
diagnostic criteria were unclear in one trial (AOM diagnosis was
made at the discretion of the clinician) (Spiro 2006).
Intervention and comparators
In two of these trials provision of an immediate antibiotic script
was compared with an antibiotic script with instructions not to
commence antibiotic treatment unless the child was not better or
was worse at 48 hours (Spiro 2006) or 72 hours (Little 2001). In
these trials, 24% (36/150) and 38% (50/132) of children in the
delayed arms reported using antibiotics at some stage during the
illness.
The other three trials compared immediate antibiotics with a
watchful waiting approach (Laxdal 1970; McCormick 2005;
Neumark 2007). In the Laxdal 1970 trial, children in the con-
trol group were closely monitored, especially during the first 48
hours and particularly when severe involvement was evident. In
the McCormick 2005 trial, antibiotics were administered to the
watchful waiting group if a child returned to the office with a treat-
ment failure or recurrence (four children in the expectant observa-
tion group had received antibiotics by day four). In the Neumark
2007 trial, 5% (4/87) of children randomised to the watchful wait-
ing group received antibiotics due to treatment failure.
Outcomes
One trial did not report any data on our primary or secondary
outcomes (Laxdal 1970), leaving four trials from which relevant
data could be extracted (Little 2001; McCormick 2005; Neumark
2007; Spiro 2006).
Pain
Data on pain at three to seven days could be derived from four
trials (959 children) (Little 2001; McCormick 2005; Neumark
2007; Spiro 2006). The data on pain from the Little 2001 trial
have been derived from data from the IPD meta-analysis (Rovers
2006), while the data onpain from theMcCormick 2005 trial have
been provided by the author. One trial (247 children) reported
data on pain at 11 to 14 days (Spiro 2006).
Adverse effects likely to be related to the use of antibiotics
(vomiting, diarrhoea or rash)
Two trials (550 children) reported data on adverse events likely to
be related to the use of antibiotics such as vomiting, diarrhoea or
rash (Little 2001; Spiro 2006).
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Abnormal tympanometry findings as a surrogate measure for
hearing problems
One trial (207 children) reported data on abnormal tympanome-
try findings at two to four weeks (McCormick 2005).
Tympanic membrane perforation
One trial (179 children) reported data on tympanic membrane
perforation (Neumark 2007).
Progression of symptoms (contralateral otitis or late AOM
recurrences)
None of the trials reported data on contralateral otitis (in unilateral
cases), while one trial (209 children) reported data on late AOM
recurrences (McCormick 2005).
Serious complications
Three trials reported on serious complications including mastoidi-
tis or meningitis (McCormick 2005; Neumark 2007; Spiro 2006),
while information on complications was not explicitly reported in
one trial (Little 2001).
Long-term effects
One trial reported data on the further ear pain episodes at three
months and one year after randomisation (Little 2001). These
long-term outcome data were collected by questionnaires. Ques-
tionnaires were returned in 219 of the 315 children (70%) that
were originally randomised at one year.
Excluded studies
We excluded 11 studies after reviewing the full text. Three
were non-randomised studies (Ostfeld 1987; Rudberg 1954; van
Buchem 1985), while three other studies had no comparison of
antibiotic with placebo or expectant observation (Casey 2012;
Engelhard 1989; Sarrell 2003). Two trials studied the effectiveness
of short- versus long-course antibiotics (Arguedas 2011; Chaput
1982), one trial studied a single-dose antibiotic with slow versus
immediate-release formulations (Liu 2011), whereas another trial
was conducted in children with ventilation tubes (Ruohola 2003).
Moreover, we excluded one trial report as this study reported on
the effectiveness of immediate versus delayed antibiotic prescrip-
tion based on a secondary analysis of a placebo-controlled trial
(Tähtinen 2012).
Risk of bias in included studies
The methodological quality of the included studies was generally
high. For further details on the risk of bias in included studies
see the ’Risk of bias’ summary (Figure 1) and ’Risk of bias’ graph
(Figure 2).
Allocation
Concealment of allocation was adequately described in 11 of the
13 included trials comparing antibiotics with placebo (Appelman
1991; Burke 1991; Damoiseaux 2000; Hoberman 2011; Howie
1972; Le Saux 2005; Mygind 1981; Tähtinen 2011; Tapiainen
2014; Thalin 1985; van Buchem 1981a and van Buchem 1981b),
and two out of five trials comparing immediate antibiotics with ex-
pectant observation (Little 2001; Spiro 2006). Random sequence
generation was adequate in seven of the 13 trials (Appelman 1991;
Burke 1991; Damoiseaux 2000; Hoberman 2011; Le Saux 2005;
Tähtinen 2011; Tapiainen 2014), and in three of the five included
trials (McCormick 2005; Neumark 2007; Spiro 2006), respec-
tively.
Blinding
All included trials in the review of antibiotics against placebo
stated that they were double-blinded. However, we judged blind-
ing to be adequate in eight of the 13 included trials (Burke 1991;
Damoiseaux 2000; Hoberman 2011; Le Saux 2005; Tähtinen
2011; Tapiainen 2014; Thalin 1985; van Buchem 1981a and van
Buchem 1981b). All five trials comparing immediate antibiotics
with expectant observation were open-label trials (Laxdal 1970;
Little 2001; McCormick 2005; Neumark 2007; Spiro 2006). As
a consequence, reporting of the child’s symptoms by parents was
not blinded in these trials. However, investigators were blinded in
two of the five trials (McCormick 2005; Spiro 2006).
Incomplete outcome data
The loss to follow-up was below 5% in eight of the 13 trials com-
paring antibiotics with placebo (Appelman 1991; Burke 1991;
Hoberman 2011; Howie 1972; Le Saux 2005; Tähtinen 2011;
Tapiainen 2014; Thalin 1985). Loss to follow-up was high in three
trials with a total loss to follow-up of 15% (van Buchem 1981a and
van Buchem 1981b), 7% (Kaleida 1991), and 12% (Damoiseaux
2000), respectively. However, one of these trials included all ran-
domised patients in the primary analysis at day four (Damoiseaux
2000). In two of the 13 trials the total number of loss to fol-
low-up/exclusions are described but it was unclear from which
treatment group children were excluded (Halsted 1968; Mygind
1981). For the review of immediate antibiotics against expectant
observation, the loss to follow-up was below 5% in two of the
five trials (McCormick 2005; Neumark 2007). The total loss to
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follow-up in the other trials was 11% (Laxdal 1970), 10% (Little
2001), and 6% (Spiro 2006), respectively.
Selective reporting
Eight of the 13 included trials comparing antibiotics with placebo
used intention-to-treat (ITT) analyses, while in the other five this
was not clear (Halsted 1968; Howie 1972; Mygind 1981; Thalin
1985; van Buchem 1981a and van Buchem 1981b). For the review
of immediate antibiotics versus expectant observation, three of the
five included trials used ITT analyses, while this was not clear in
the other two trials (Laxdal 1970; Neumark 2007).
Other potential sources of bias
Noother potential sources of bias could be detected in the included
trials, except for the Laxdal 1970 trial, which we judged as having a
high risk of detection bias since children in the control group were
subjected to very close scrutiny, especially during the first 48 hours
and particularly when severe involvement was evident. However,
this trial did not report any data on our primary or secondary
outcomes.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
versus placebo for acute otitis media in children
Antibiotics versus placebo
Primary outcomes
1. Proportion of children with pain at various time points
The combined results of the trials revealed that by 24 hours from
the start of treatment, 60% of the children had recovered whether
or not they had placebo or antibiotics. The proportion of children
that recovered spontaneously at two to three days, four to seven
days and 10 to 12 days was 84%, 76% and 78%, respectively.
Antibiotics achieved a 30% (95% confidence interval (CI) 14%
to 43%) relative reduction in the risk of pain at two to three days,
24% (95% CI 9% to 37%) relative reduction in the risk of pain
at four to seven days and 67% (95% CI 34% to 83%) relative
reduction in the risk of pain at 10 to 12 days (Analysis 1.1). This
means 5% (95% CI 2% to 7%) fewer children had pain after two
to three days (number needed to treat for an additional beneficial
outcome (NNTB) 20, 95%CI 14 to 50), 6% (95%CI 2% to 9%)
fewer children had pain after four to seven days (NNTB 16, 95%
CI 11 to 50) and 14% (95% CI 6% to 22%) fewer children had
pain after 10 to 12 days (NNTB 7, 95% CI 4 to 16), respectively.
Plots of the event rate (pain) in the treatment and control groups
for each study at 24 hours and two to three days are reported in
Figure 3 and Figure 4. The funnel plot for pain at the various time
points did not reveal asymmetry (Figure 5).
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Figure 3. L’Abbé plot of the rates of pain at 24 hours for the placebo (control) versus antibiotic
(experimental) group.
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Figure 4. L’Abbé plot of the rates of pain at two to three days for the placebo (control) versus antibiotic
(experimental) group.
16Antibiotics for acute otitis media in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 5. Funnel plot of comparison: 1 Antibiotic versus placebo, outcome: 1.1 Pain.
Quality of the evidence
We judged the data on pain at 24 hours, two to three days and four
to seven days to be of high quality, while we judged the data on
pain at 10 to 12 days to be of moderate quality. We downgraded
the evidence for pain at days 10 to 12 from high quality as this
outcomewas not specified a priori in this trial (secondary analysis).
2. Adverse effects likely to be related to the use of antibiotics
Antibiotics resulted in a 38% (95% CI 15% to 73%) relative in-
crease in the risk of adverse effects likely to be related to the use of
antibiotics (defined as vomiting, diarrhoea or rash) compared with
placebo; 27% (283/1044) of children treated with antibiotics ver-
sus 20% (208/1063) of children treated with placebo experienced
vomiting, diarrhoea or rash (Analysis 1.2). The number needed
to treat for an additional harmful outcome (NNTH) was 14 (9 to
26).
Quality of the evidence
We judged the evidence for adverse effects likely to be related to
the use of antibiotics (vomiting, diarrhoea or rash) to be of high
quality.
Secondary outcomes
1. Abnormal tympanometry findings at various time points
Antibiotics achieved an 18% (95% CI 10% to 26%) relative re-
duction in the risk of abnormal tympanometry findings at two to
four weeks, and a 12% (95% CI 0% to 22%) relative reduction in
the risk of abnormal tympanometry findings at six to eight weeks
(Analysis 1.3). This means 9% (95% CI 5% to 13%) fewer chil-
dren had abnormal tympanometry findings at two to four weeks
(NNTB 11, 95% CI 7 to 20) and 6% (95% CI 0% to 12%)
fewer childrenhad abnormal tympanometry findings at six to eight
weeks (NNTB 16, 95% CI 8 to 277), respectively.
However, antibiotics were not associated with a statistically signif-
icant reduction in the risk of abnormal tympanometry findings
at three months compared with placebo (Analysis 1.3). Further-
more, audiometry was done in only two studies and incompletely
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reported. The two studies that used audiograms were van Buchem
1981a and Kaleida 1991: (i) van Buchem 1981a reported that,
“After one month, 31% of the patients showed an air/bone gap of
more than 20 dB. After two months, this was still the case with
19% of the patients. Here again, there were no significant differ-
ences between the groups”; (ii) Kaleida 1991 stated that “Analysis
of hearing acuity in children two years of age and older indicated
that elevated hearing thresholds ... bore no apparent relationship
... to mode of treatment (amoxicillin versus placebo)”.
Quality of the evidence
We judged the evidence for abnormal tympanometry findings at
the various time points to be of high quality.
2. Tympanic membrane perforation
Antibiotic treatment was associated with a 63% (95% CI 24% to
82%) relative reduction in the risk of tympanic membrane perfo-
ration compared with placebo (Analysis 1.4). However, absolute
benefits of antibiotics appeared to be small: 3% (95% CI 1% to
5%) fewer children had a tympanicmembrane perforation. There-
fore, 33 children (95% CI 20 to 100) needed to be treated to pre-
vent one child experiencing a tympanic membrane perforation.
Quality of the evidence
We judged the evidence for tympanic membrane perforation to
be of high quality.
3. Contralateral otitis
Antibiotics were associated with a 51% (5% to 75%) relative re-
duction in the development of contralateral otitis compared with
placebo (Analysis 1.5). This means 9% (95% CI 5% to 13%)
fewer children had contralateral otitis (NNTB 11, 95% CI 7 to
20).
Quality of the evidence
We judged the evidence for contralateral otitis to be of high quality.
4. AOM recurrences
Antibiotics were not associated with a statistically significant re-
duction in the occurrence of late AOMrecurrences compared with
placebo (Analysis 1.6). AOM recurrences were common. Burke
1991 stated “The mean number of recorded recurrences of oti-
tis media or acute red ear was 0.70 (range 0 to 4) in the antibi-
otic group and 0.63 (range 0 to 7) in the placebo group and this
difference was not significant (difference 0.06, 95% CI -0.22 to
0.339).” Six other trials reported the proportions who relapsed;
combined, these give a risk ratio (RR) of 0.93 (95% CI 0.78 to
1.10), which is consistent with Burke’s findings.
Quality of the evidence
We judged the evidence for late AOM recurrences to be of high
quality.
5. Serious complications related to AOM
Few serious complications occurred in either the antibiotic treat-
ment group or the control group. In just over 3000 children stud-
ied, only one case of mastoiditis occurred in both the antibiotic
group (Mygind 1981) and the placebo group (Hoberman 2011).
Moreover, one child suffered frommeningitis (Damoiseaux 2000),
pneumococcal bacteraemia and radiologically confirmed pneumo-
nia (Hoberman 2011) in the placebo group andone child had tran-
sient facial paralysis in the antibiotic group (Kaleida 1991).Hence,
the applicability of these findings to groups of children in whom
serious complications such as mastoiditis is common is uncertain.
One of the excluded studies did report high rates of mastoiditis
(Rudberg 1954). This was an open, semi-randomised study con-
ducted in Sweden in 1954. Participants were randomised by case-
sheet number but a proportion (about 30 of 220) requested, and
were granted, entry to the penicillin group. The rate of mastoiditis
was 17% in the untreated group versus 1.5% in the sulphonamide-
treated group and 0% in the penicillin-treated group. The biases
of this study (semi-randomisation and unblinded outcome assess-
ment) are unlikely to explain such a large difference.
Quality of the evidence
We judged the evidence for serious complications to be of moder-
ate quality. We downgraded the evidence from high quality as we
considered the sample size to be insufficient to draw any definite
conclusions based on these data and due to the conflicting results
found in an open, semi-randomised study that was not included
in our review.
6. Long-term effects
Based on reviewing children’s notes, antibiotics were not associated
with a statistically significant reduction in the number of secondary
care referrals at one year after randomisation: 7/110 (6%) in the
antibiotic group and 9/111 (8%) in the placebo group (RR 0.78,
95% 0.30 to 2.03).
Based on questionnaires returned by parents approximately 3.5
years after initial randomisation, antibiotics were associated with
a 46% (95% CI 8% to 97%) relative increase in the risk of AOM
recurrences. Thismeans 20% (95%CI 5% to 35%) fewer children
had AOM recurrences (NNTB 5, 95% CI 2 to 20). No between-
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group differences were observed for secondary care referrals. Fur-
thermore, antibiotics were not associated with a statistically sig-
nificant reduction in the number of ear, nose and throat surgeries
(RR 0.68, 95% CI 0.40 to 1.17).
Quality of the evidence
We judged the evidence for long-term effects at one year to be of
high quality, while we judged the 3.5 years data to be of moderate
quality. We mainly downgraded the evidence from high quality
because of the high proportion of children that were not included
in the analysis (30%), which introduced a significant risk of (at-
trition) bias.
Immediate antibiotics versus expectant observation
Primary outcomes
1. Proportion of children with pain at various time points
Immediate antibiotics were not associated with a statistically sig-
nificant reduction in the risk of pain at three to seven days (RR
0.75, 95% CI 0.50 to 1.12) and 11 to 14 days (RR 0.91, 95% CI
0.75 to 1.10) compared with expectant observation (observation
with or without an antibiotic prescription) (Analysis 2.1).
Quality of the evidence
We judged the data on pain at three to seven days to be of high
quality, while we judged the data on pain at 11 to 14 days to be of
moderate quality. We downgraded the evidence for pain at days
11 to 14 from high quality because of the substantial number of
children that were ’lost to follow-up’ (13%), which introduced a
risk of (attrition) bias.
2. Adverse effects likely to be related to the use of antibiotics
Immediate antibiotics were associated with a 71% (95% CI 24%
to 136%) relative increase in the risk of adverse effects likely to
be related to the use of antibiotics (defined as vomiting, diarrhoea
or rash) compared with expectant observation; 29% (77/268) of
children treated with immediate antibiotics versus 17% (47/282)
of children treated with expectant observation experienced vom-
iting, diarrhoea or rash (Analysis 2.2). The NNTH was 9 (6 to
20).
Quality of the evidence
We judged the evidence for adverse effects likely to be related to
the use of antibiotics (vomiting, diarrhoea or rash) to be of high
quality.
Secondary outcomes
1. Abnormal tympanometry findings at various time points
In one trial (207 children), the proportion of children with abnor-
mal tympanometry findings at four weeks did not substantially
differ between those receiving immediate antibiotics and expec-
tant observation (RR 1.03, 95% CI 0.78 to 1.35) (Analysis 2.3).
Quality of the evidence
We judged the data on abnormal tympanometry findings at four
weeks to be of moderate quality. We downgraded the evidence
from high quality as the number of children that were ’lost to
follow-up’ in the immediate antibiotics group was substantially
lower than in the expectant observation group (4% versus 11%),
thereby introducing a risk of (attrition) bias.
2. Tympanic membrane perforation
No tympanic membrane perforations were observed in either
group in the only trial (179 children) reporting on this outcome
(Analysis 2.4).
Quality of the evidence
We judged the data on tympanic membrane perforation to be of
moderate quality. We downgraded the evidence from high quality
as we considered the sample size to be insufficient to draw any
definite conclusions based on these data
3. Contralateral otitis
None of the trials reported data on contralateral otitis.
4. AOM recurrences
In one trial (209 children), immediate antibiotics were associated
with a non-statistically significant 41% (95% CI -26% to 169%)
relative increase in the risk of AOM recurrences (Analysis 2.5).
Quality of the evidence
We judged the data on late AOM recurrences to be of moderate
quality. We downgraded the evidence from high quality as the
number of children that were ’lost to follow-up’ in the immediate
antibiotics group was substantially lower than in the expectant
observation group (3% versus 10%), thereby introducing a risk of
(attrition) bias.
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5. Serious complications related to AOM
No serious complications occurred in either the immediate antibi-
otic group or the expectant observation group.
Quality of the evidence
We judged the evidence for serious complications to be of moder-
ate quality. We downgraded the evidence from high quality as we
considered the sample size to be insufficient to draw any definite
conclusions based on these data.
6. Long-term effects
No statistically significant differences were observed between the
immediate antibiotics and the delayed antibiotics group in parent-
reported ear pain episodes at one year (odds ratio (OR) 1.03, 95%
0.60 to 1.78).
Quality of the evidence
We judged the evidence for long-term effects to be of moderate
quality. We mainly downgraded the evidence from high quality as
this evidence was derived from a secondary analysis and because
of the high proportion of children that were not included in the
analysis at one year (30%), which introduced a significant risk of
(attrition) bias.
Individual patient data (IPD) meta-analysis to identify
children most likely to benefit from antibiotic
treatment
In 2006, an individual patient data (IPD) meta-analysis was per-
formed, Rovers 2006, using data from six high-quality RCTs, in-
cluding a total of 1643 children, which were also included in
this review as individual trials (Appelman 1991; Burke 1991;
Damoiseaux 2000; Le Saux 2005; Little 2001;McCormick 2005).
The main findings of this IPD meta-analysis were that significant
effect modifications were noted for age and bilateral AOM and
for otorrhoea; in children aged less than two years with bilateral
AOM, 55% of the control group and 30% of the antibiotics group
still had pain, fever or both at three to seven days (absolute risk
reduction of 25%, 95% CI 14% to 36%; NNTB 4). In children
aged two years or older with bilateral AOM the absolute risk re-
duction was 12% (95% CI -1% to 25%; P value for interaction
= 0.022). Among children with otorrhoea, 60% of those in the
control group had pain, fever or both at three to seven days versus
24% in the antibiotics group (risk reduction of 36%, 95% CI
19% to 53%; NNTB 3). The absolute reduction in risk among
those without otorrhoea was 14% (95% CI 5% to 23%; NNTB
8; P value for interaction = 0.039). No differences were identified
for age alone.
Quality of the evidence
We judged the evidence for subgroup analyses based on the IPD
meta-analysis to be of high quality.
D I S C U S S I O N
Summary of main results
This review reveals that antibiotics have no early effect on pain, a
slight effect on pain in the days following and only a modest effect
on the number of children with tympanic perforations, contralat-
eral otitis episodes and abnormal tympanometry findings at two
to four weeks and at six to eight weeks, compared with placebo
in children with acute otitis media (AOM). However, in applying
these results, there are a number of issues to consider, including
the individual potential for serious complications and subgroups
of children in whom there may be greater benefits.
Overall completeness and applicability of
evidence
Does the effect vary in different clinical groups? Our number
needed to treat for an additional beneficial outcome (NNTB) of
20 for pain at days two to three days, 16 for pain at four to seven
days and seven for pain at 10 to 12 days is for the ’average’ case
and may vary in subgroups. Several studies reported higher rates
of failure of placebo treatment among children less than two years
of age and those with bilateral disease (Appelman 1991; Burke
1991; Damoiseaux 2000; Hoberman 2011; Tähtinen 2011), and
another trial has suggested that most benefit is seen in children
with high fever or vomiting (Little 2001). Moreover, some studies
found that children with bilateral AOMdiffer with regards to clin-
ical and microbiological (increased presence of (non-typeable) H.
influenzae) characteristics compared with children with unilateral
AOM (Barkai 2009; McCormick 2007). However, the individual
patient data (IPD) meta-analysis demonstrated that the relative
effects of antibiotics were not significantly modified by either age
or bilateral disease alone but the absolute differences were larger in
the younger patients (less than two years) with bilateral disease and
in children with both AOM and otorrhoea (Rovers 2006). Further
analysis of these data has shown that age younger than two years
is an independent predictor of the development of asymptomatic
middle-ear effusion (Koopman 2008). This analysis also found
that antibiotic therapy has a marginal effect on the development
of asymptomatic middle-ear effusion in children with AOM.
Does the impact vary by duration and dose of antibiotics? Most
trials use seven days of antibiotic treatment. One recentmeta-anal-
ysis of a short (less than seven days) versus long (more than seven
days) course of antibiotics reported that risk of treatment failure at
one month was higher with short courses of antibiotics (odds ratio
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(OR) 1.34, 95% confidence interval (CI) 1.15 to 1.55) (Kozyrskyj
2010). However, the absolute difference in treatment effect was
small (3%) and short courses of antibiotics were associated with a
statistically significant reduction in gastrointestinal adverse events
compared with longer courses. A recommendation regarding the
most appropriate dose of antibiotics is not possible due to a lack
of sufficient data.
What are the potential consequences of not using antibiotics? Be-
sides the immediate pain associated with AOM, there are some
more serious complications. Though only two cases of mastoiditis
were reported in the included trials (one child received antibiotics
and one child was assigned to placebo), a semi-randomised trial
in Sweden in 1954 reported a rate of 17% in the untreated group
versus none in the penicillin-treated groups (Rudberg 1954). In
populations or sub-populations where mastoiditis is still judged a
frequent problem, such as in some low-income countries, antibi-
otic treatment would be strongly advised (Berman 1995).
Of note is an article that revealed that doctors commonly over-
diagnose AOM (Rothman 2003). What effect might this have on
the efficacy of antibiotics (or any treatment)? One effect will be
to blunt any treatment effect by dilution (from the cases of non-
AOM). The results of two recently performed trials (Hoberman
2011; Tähtinen 2011), in which AOM has been diagnosed with
the use of stringent criteria (including pneumatic otoscopic exam-
ination in one trial (Tähtinen 2011), underline this phenomenon.
Nevertheless, physicians in daily practice are likely to use the same
diagnostic methods (perhaps even less stringent) as used in the
majority of the included trials in this review. As a consequence,
the effectiveness of antibiotics reported in this review is likely to
be a true reflection of the effectiveness in actual clinical practice.
However, if new and more accurate diagnostic procedures are in-
troduced in future daily practice, then the current estimate of ef-
fectiveness will have to be reconsidered.
Quality of the evidence
The methodological quality of the included studies was generally
high. We judged the evidence to be of high quality for most of the
outcomes in the review of antibiotics against placebo. We judged
the quality of evidence to be moderate for pain at 10 to 12 days,
serious complications and long-term effects (3.5 years data). We
downgraded the evidence mainly because of the risk of reporting
bias (pain at 10 to 12 days), sample size considerations (serious
complications) and the risk of attrition bias (long-term effects).
For the review of immediate antibiotics versus expectant observa-
tion, we judged the evidence to be of moderate quality for most
of the outcomes. We downgraded the evidence mainly because of
sample size considerations (tympanic membrane perforation, se-
rious complications) and the risk of attrition bias (pain at days 11
to 14, abnormal tympanometry findings at four weeks, late AOM
recurrences, long-term effects). We judged the evidence to be of
high quality for pain at days four to seven and adverse effects likely
to be related to the use of antibiotics.
Potential biases in the review process
There was some clinical heterogeneity among the included trials.
For example, patients were recruited from different settings (gen-
eral practice, ear, nose and throat and paediatric clinics). How-
ever, the majority of included trials did use a diagnostic method
(clinical diagnosis of AOM as inclusion criteria) that resembles
daily clinical practice. Besides, duration and dosage of the antibi-
otic treatment varied to some extent. For the review of antibiotics
against placebo, the duration of antibiotic treatment varied from
seven to 14 days. However, we do not consider this as a major
drawback since most trials used seven days of antibiotic treatment
and current evidence indicates only a small absolute treatment dif-
ference (3%) in treatment failure at one month in favour of a long
(more than seven days) versus a short (less than seven days) course
of antibiotics. Moreover, the primary outcome of this review (pro-
portions of children with pain) is reported within the first seven
days of antibiotic treatment. In addition, we assessed funnel plots
for potential reporting biases for the primary analysis (Figure 5).
No asymmetry could be detected in the included trials.
Agreements and disagreements with other
studies or reviews
This review demonstrated that at 24 hours pain had recovered
spontaneously in 60% of children and that themajority had recov-
ered in the following two to 12 days regardless of whether they had
received placebo or antibiotics. However, the IPD meta-analysis,
which included six of the trials included in this review, revealed a
slower rate of recovery (Figure 6) with only 22% of children expe-
riencing spontaneous recovery at 24 hours (Rovers 2006). There
are a number of possible explanations for this. First, data from
older trials were not included in the IPD meta-analysis and con-
sequently the study population may reflect a higher threshold of
doctor visitation; for example, the children may be ’sicker’ or pre-
senting to the doctor later in the course of their illness. Variation in
the definitions of pain/no pain cut-offs among the trials included
in the reviews may also explain some of this variation. From the
IPD meta-analysis survival curve (Figure 6) it can be seen that
antibiotics had greatest effect compared with placebo at day three.
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Figure 6. Percentage with pain based on the subset of six studies included in the IPD meta-analysis (Rovers
2006).
A previous meta-analysis has examined the question of whether
antibiotics were indicated for AOM in children and concluded
that the answer is a qualified ’yes’ (Rosenfeld 1994). It estimated
a NNTB of seven for “primary control” (complete clinical res-
olution), compared with our NNTB of 20 for symptom relief.
The difference may be the consequence of our focus on patient-
oriented outcomes, such as pain, rather than clinical signs, such
as eardrum appearance. The previous systematic review suggests
that where mastoiditis is not a concern, primary care physicians
could weigh the benefits against the risks of adverse effects from
antibiotics with their patients. This statement is in agreement with
the findings of our review as adverse events such as diarrhoea,
vomiting or rash were more common in children receiving an-
tibiotics. In the IPD meta-analysis the most commonly described
adverse effect of antibiotic treatment was diarrhoea, ranging from
2% to 14% in controls and from 4% to 21% in those given an-
tibiotics (Rovers 2006). Occurrence of rash ranged from 2% to
6% in the control groups and from 1% to 8% in the antibiotic
groups. A recent systematic review and meta-analysis on common
harms of amoxicillin revealed that harms were poorly reported in
most placebo-controlled trials (Gillies 2014). In this review, di-
arrhoea was attributed to amoxicillin only in the form of amoxi-
cillin/clavulanate. Amoxicillin did increase the risk of candidiasis
compared with placebo, but no association between amoxicillin
and rash or vomiting was observed (Gillies 2014). Bacterial resis-
tance to antibiotics is also a consideration, with an association be-
tween antibiotic use and resistant bacteria demonstrated for many
important pathogens (Arnold 2005).
Several trials evaluated amanagement approach forAOMinwhich
an expectant observational approach is used (Laxdal 1970; Little
2001; McCormick 2005; Neumark 2007; Spiro 2006). In one
of these trials pain and malaise at day three were greater among
those randomised to receive an antibiotic prescription with advice
to fill it only if there was no improvement after 72 hours com-
pared with those receiving immediate antibiotics (Little 2001).
In a secondary analysis of the trial no difference was found be-
tween delayed and immediate treatment groups in ear function
and ear pain at three and 12 months (Little 2006). Another study
using a similar prescribing approach and examining clinical out-
comes at four to six days found no difference between immedi-
ate and delayed antibiotic groups (Spiro 2006). In the third study
(McCormick 2005), immediate antibiotic treatment was associ-
ated with decreased numbers of treatment failures and improved
symptom control at day four and day 12 compared with those
allocated to expectant observation with no prescription. Neumark
2007, in a similar comparison, found that immediate antibiotics
provided some symptomatic benefit; children who received an-
tibiotics had less pain, used fewer analgesics and consulted less
during the first seven days. Meta-analysis of data from these four
trials found no difference in pain between immediate antibiotics
and expectant observational approaches at three to seven days. An-
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other review (Spurling 2013), which evaluated the effect of delayed
versus immediate or no antibiotics for respiratory infections and
which included two studies on AOM (Little 2001; Spiro 2006),
concluded that immediate antibiotics was the strategy most likely
to provide the best clinical outcomes for AOM. One randomised
study found that observation therapy with or without a prescrip-
tion in children with AOM was well accepted by parents (Chao
2008). Antibiotic use was less in those randomised to observation
without prescription and no complications were reported.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antibiotics produce a (small) reduction in the number of children
with pain at two to three days (number needed to treat for an addi-
tional beneficial outcome (NNTB) 20), four to seven days (NNTB
16) and 10 to 12 days (NNTB 7) from initial assessment, and
reduce the number of children with tympanic membrane perfo-
rations (NNTB 33), contralateral otitis episodes (NNTB 11) and
abnormal tympanometry findings at two to four weeks (NNTB
11) and six to eight weeks (NNTB 16) compared with placebo.
However, in high-income countries, most cases of acute otitis me-
dia (AOM) spontaneously remit without complications. The ben-
efits of antibiotics must be weighed against the possible harms: for
every 14 children treated with antibiotics one child experienced
an adverse event (such as vomiting, diarrhoea or rash) that would
not have occurred if antibiotics were withheld. Therefore manage-
ment should emphasise advice about adequate analgesia and the
limited role for antibiotics. Antibiotics are most useful in children
under two years of age with bilateral AOM, or with both AOM
and otorrhoea. For most other children with mild disease, an ex-
pectant observational approach seems justified. Cates has devel-
oped an appropriate handout and tested this together with an op-
tional antibiotic prescription (Cates 1999). The handout is avail-
able at www.nntonline.net/ebm/main pages/AOM.asp (accessed
22 November 2012).
Implications for research
Further research is needed to determine if it is possible to predict
which children are more likely to suffer from the complications
of AOM and whether an expectant observation approach can be
safely applied to children with mild AOM in low-income coun-
tries.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Appelman 1991
Methods Randomised - yes, computer-generated random numbers
Concealment of allocation - adequate
Double-blind - yes, blinding procedure not described
Intention-to-treat (ITT) - unclear
Loss to follow-up - described
Design - parallel
Participants N - 126 children (N = 121 children included in analysis)
Age - between 6 months and 12 years
Setting - general practice and secondary care in the Netherlands; confirmation of diag-
nosis and randomisation were done by otorhinolaryngologists
Inclusion criteria - recurrence of acute otitis media (AOM) characterised by a (sub)
acute onset, otalgia and otoscopic signs of middle-ear infection within 4 weeks to 12
months of the previous attack
Exclusion criteria - antibiotic treatment < 4 weeks prior to randomisation, previous
participation in this study, contraindication for penicillin, serious concurrent disease that
necessitated antibiotic treatment
Baseline characteristics - balanced
Interventions Tx - amoxicillin/clavulanate (weight tailored dose) for 7 days; N = 70 (N = 67 included
in analysis)
C - matching placebo for 7 days; N = 56 (N = 54 included in analysis)
Use of additional medication - each child was given analgesics (paracetamol) as long
as earache was present and decongestive nose drops for 1 week
Outcomes Primary outcome - treatment failure (i.e. presence of otalgia or fever > 38 °C or both
at 3 days)
Assessment by (blinded) general practitioner at 3 days on the presence or absence of fever
(> 38 °C) and otalgia and 14 days on the presence or otorrhoea
Assessment by otorhinolaryngologist at 1 month of otoscopy, tympanometry and in
children > 3 years of age an audiogram
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Treatment allocated by otolaryngologist
(independent to trial personnel); treatment
code placed in sealed envelopes
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Appelman 1991 (Continued)
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Identical taste and appearance to amox-
icillin/clavulanate and placebo not de-
scribed
Incomplete outcome data (attrition bias) Low risk Loss to follow-up - treatment: N = 3 (4%)
and placebo: N = 2 (4%) due to loss of their
registration forms
Burke 1991
Methods Randomised - yes, computer-generated random numbers
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - not described
Design - parallel
Participants N - 232 children
Age - between 3 and 10 years
Setting - general practice; 48 general practitioners in 17 general practices in Southamp-
ton, Bristol and Portsmouth (UK)
Inclusion criteria - acute earache and at least 1 abnormal eardrum
Exclusion criteria - antibiotic treatment or acute otitis media (AOM) < 2 weeks prior
to randomisation, strong indication for antibiotic treatment according to general prac-
titioner, contraindication for amoxicillin, serious chronic conditions
Baseline characteristics - slight imbalance in gender (boys treatedwith antibiotics versus
boys treated with placebo = 52% versus 42%) and figure 1 appears to demonstrate that
fewer children were crying at baseline (0 hours) in the amoxicillin arm compared with
the placebo arm, suggesting a failure of randomisation
Interventions Tx - amoxicillin 250 mg 3 times daily for 7 days; N = 114 (N = 114 included in analysis
for short-term outcome)
C - matching placebo 3 times daily for 7 days; N = 118 (N = 118 included in analysis
for short-term outcome)
Use of additional medication - analgesics (paracetamol 120 mg/5 mL) for pain as
needed
Outcomes Main outcomes were divided into short-term, middle-term and long-term:
Short-term - (a) duration of symptoms; (b) use of analgesics (assessed by weighing
bottles); (c) clinical signs at 1 week; (d) incidence of complications; (e) treatment failure
(i.e. second-line antibiotics were required)
Middle-term - (a) tympanometry findings at 1 and 3 months
Long-term - (b) number of AOM episodes in 12 months; (b) number of specialist
referrals
Home visits by researcher at day 1, days 4 to 6 and general practitioner visit at day 7
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Burke 1991 (Continued)
Symptom diary kept by parents for 21 days
Notes It is not clear whether the “discharging ears” inTable 1 should be included as perforations,
we now included the number of perforations as summarised in Table 2 in our analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Randomisation was carried out indepen-
dently of the investigators; randomisation
code was kept sealed and was unknown to
any of the participants in the study
Other bias Unclear risk ITT analysis - yes; baseline characteristics -
imbalance for gender and crying
Blinding of participants and personnel
(performance bias)
Low risk Each bottle was identified only by number
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up - not described; all ran-
domised patients included in short-out-
come analysis
Damoiseaux 2000
Methods Randomised - yes, computerised 2 block randomisation
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 240 children (N = 212 children included in analysis)
Age - between 6 months and 2 years
Setting - general practice; 53 general practitioners (GPs) in the Netherlands
Inclusion criteria - acute otitis media (AOM) defined as infection of the middle ear
of acute onset and a characteristic eardrum picture (injection along the handle of the
malleus and the annulus of the tympanicmembrane or a diffusely red or bulging eardrum)
or acute otorrhoea. In addition 1 or more symptoms of acute infection (fever, recent
earache, general malaise, recent irritability)
Exclusion criteria - antibiotic treatment < 4weeks prior to randomisation, contraindica-
tion for amoxicillin, comprised immunity, craniofacial abnormalities, Down’s syndrome
or being entered in this study before
Baseline characteristics - slight imbalance in the prevalence of recurrent AOM, regular
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Damoiseaux 2000 (Continued)
attendance at a daycare centre and parental smoking; logistic regression was used to
adjust for these imbalances
Interventions Tx - amoxicillin suspension 40 mg/kg/day 3 times daily for 10 days; N = 117 (N = 107
included in analysis for short-term outcome)
C - matching placebo suspension for 10 days; N = 123 (N = 105 included in analysis
for short-term outcome)
Use of additional medication - all children received decongestive nose drops for 7
days; analgesics (paracetamol, children < 1 year: 120 mg suppository, > 1 year: 240 mg
suppository) was allowed
Outcomes Primary outcome - persistent symptoms at day 4: assessed by the doctor and defined as
persistent earache, fever > 38 °C, crying or being irritable. Additionally, prescription of
another antibiotic because of clinical deterioration before the first follow-up visit was to
be considered a persistent symptom
Secondary outcomes - (a) clinical treatment failure at day 11 (i.e. persistent fever,
earache, crying, being irritable or no improvement of tympanic membrane (including
perforation); (b) duration of fever, pain or crying; (c) mean number of doses analgesics
given; (d) adverse effects mentioned in diaries; (e) percentage of children with middle-
ear effusion at 6 weeks (i.e. combined otoscopy and tympanometry)
Follow-up visits at the GP’s clinic were scheduled at day 4 and 11; home visit at 6
weeks by the researcher collecting data of symptoms, referrals and both otoscopy and
tympanometry was performed
Parents were instructed to keep a symptom diary for 10 days
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised 2 block randomisation
Allocation concealment (selection bias) Low risk Randomisation was carried out indepen-
dently of the investigators; randomisation
code was kept in pharmacy of the Univer-
sity Medical Centre Utrecht
Other bias Low risk ITT analysis - yes, baseline characteristics
- slight imbalance, logistic regression was
used to adjust for imbalances in prognostic
factors
Blinding of participants and personnel
(performance bias)
Low risk Placebo suspension with same taste and ap-
pearance as amoxicillin
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Damoiseaux 2000 (Continued)
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up/exclusion from analysis
(received other antibiotics or had grommets
inserted) - treatment: N = 10 (9%) and
placebo: N = 18 (15%). However, for pri-
mary analysis of symptoms at day 4 all ran-
domised patients were included
Halsted 1968
Methods Randomised - yes, pre-determined code, which was unknown to physician; method of
random sequence generation unclear
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - described, unclear from which treatment group patients were ex-
cluded
Design - parallel
Participants N - 106 children (N = 89 children included in analysis; N = 12 children were excluded
because they did not adhere to the double-blind protocol; N = 5 children lost to follow-up
or excluded because of persistent fever, development of complication requiring antibiotic
treatment or if group A streptococci was cultured from the middle ear)
Age - between 2 months and 5.5 years
Setting - secondary care: paediatric department of Cleveland (USA)
Inclusion criteria - AOM based on otoscopic findings; most of the cases had bulging
membrane with loss of normal light reflex and landmarks, in a few the eardrum was only
diffusely red
Exclusion criteria - antibiotic treatment < 10 days prior to randomisation, associated
bacterial infection requiring antibiotic treatment, rupture of tympanic membrane, con-
traindication for study drugs
Baseline characteristics - not described
Interventions Tx 1 - ampicillin 100 mg/kg/day 4 daily for 10 days; N = ? (N = 30 included in analysis)
Tx 2 - pheneticillin 30 mg/kg/day 4 daily and sulfisoxazole 150 mg/kg/day 4 daily for
10 days; N = ? (N = 32 included in analysis)
C - placebo for 10 days; N = ? (N = 27 included in analysis)
Use of additional medication - phenylephrine nose drops and aspirin for children over
6 months was prescribed as necessary; no other medications were employed
Outcomes Primary outcome - early improvement defined as defervescence and decrease of symp-
toms at 24 to 72 hours
Secondary outcomes - (a) late improvement defined as resolution of symptoms and
normal tympanic membrane at 14 to 18 days, (b) bacteriological cultures
Notes -
Risk of bias
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Halsted 1968 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Pre-determined code, which was unknown
to physician; method of random sequence
generation unclear
Allocation concealment (selection bias) Unclear risk Method not described
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - not described
Blinding of participants and personnel
(performance bias)
Unclear risk Identical taste and appearance to antibi-
otics and placebo not described
Incomplete outcome data (attrition bias) Unclear risk Reasons described, unclear from which
treatment group patients were excluded
Hoberman 2011
Methods Randomised - yes, stratified block randomisation with computer-generated randomisa-
tion lists
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 291 (N = 291 included in analysis)
Age - between 6 months and 2 years
Setting - secondary care; children’s hospital of Pittsburgh and a private paediatric clinic
in Kittanning (USA)
Inclusion criteria - children needed to have received at least 2 doses of pneumococcal
conjugate vaccine and to have acute otitis media (AOM) as defined on the basis of 3
criteria: (a) the onset (i.e. within the preceding 48 hours) of symptoms that parents rated
with a score of at least 3 on the acute otitis media - severity of symptoms (AOM-SOS)
scale (on which scores range from 0 to 14, with higher scores indicating greater severity of
symptoms), (b) the presence of middle-ear effusion and (c) moderate or marked bulging
of the tympanic membrane or slight bulging accompanied by either otalgia or marked
erythema of the membrane
All the study clinicians were otoscopists who had successfully completed an otoscopic
validation programme
Exclusion criteria - antibiotic treatment < 96 hours prior to randomisation, concomitant
acute illness (e.g. pneumonia) or a chronic illness (e.g. cystic fibrosis), contraindication
to amoxicillin, presence of otalgia for more than 48 hours, perforation of the tympanic
membrane
Baseline characteristics - balanced
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Hoberman 2011 (Continued)
Interventions Tx - amoxicillin-clavulanate 90-6.4 mg/kg daily in 2 doses for 10 days; N = 144 (N =
139 were assessed at day 4 to 5)
C - matching placebo in 2 doses for 10 days; N = 147 (N = 142 were assessed at day 4
to 5)
Use of additional medication - acetaminophen (paracetamol) as needed for symptom
relief
At each visit children were categorised as having met the criteria for either clinical success
or clinical failure
Children who met the criteria for clinical failure were treated with a standardised 10-
day regimen of orally administered amoxicillin (90 mg/kg daily) and cefixime (8 mg/kg
daily)
Outcomes Primary outcomes - (a) time to resolution of symptoms (i.e. time to the first recording
of an AOM-SOS score of 0 or 1 and the time to the second of 2 successive recordings
of that score; (b) symptom burden over time (i.e. mean AOM-SOS score over time each
day for the first 7 days of follow-up and groups’ weighted mean scores for that period)
Secondary outcomes - (a) clinical failure at day 4 to 5; (b) clinical failure at day 10
to 12; (c) use of acetaminophen (paracetamol); (d) occurrence of adverse events; (e)
nasopharyngeal colonisation rates; (f ) use of healthcare resources; (g) relapses
Clinical failure was defined at or before the day 4 to 5 visit as either a lack of substantial
improvement in symptoms, a worsening of signs on otoscopic examination, or both and
at the day 10 to 12 visit as the failure to achieve complete or nearly complete resolutions of
symptoms and otoscopic signs, without regard to the persistence of resolution of middle-
ear effusion. Once a child had met the criteria for clinical failure, he or she remained in
that category for the analysis
Daily symptoms were assessed with the use of a structured interview of 1 of the child’s
parents until the first follow-up visit; visits were scheduled at day 4 or 5, day 10 to 12
(end of treatment) and at day 21 to 25
Patients were asked to complete a diary twice a day for 3 days and once a day thereafter
Notes This study did not report pain data that could be used for the review comparing antibi-
otics with placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified block randomisation with com-
puter-generated randomisation lists
Allocation concealment (selection bias) Low risk A pharmacist (independent of the trial
team) provided masked study medica-
tion bottles with amoxicillin/clavulanate or
placebo
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
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Hoberman 2011 (Continued)
Blinding of participants and personnel
(performance bias)
Low risk Placebo with same taste and appearance as
amoxicillin-clavulanate
Incomplete outcome data (attrition bias) Low risk Children not assessed at day 4 to 5 - treat-
ment: N = 5 (3%) and placebo: N = 5 (3%)
. All randomised patients included in anal-
ysis
Howie 1972
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - not described
Design - parallel
Participants N - 280 children
Age - 2.5 years or younger
Setting - secondary care: general paediatric practice in Huntsville (USA)
Inclusion criteria - acute otitis media (AOM) as clinically diagnosed by the participating
paediatricians
Exclusion criteria - if researchers felt that parents would not accept diagnostic aspiration,
when condition of the patient required immediate antibiotic treatment
Baseline characteristics - not described
Interventions Tx 1 - erythromycin estolate 125 mg/5 mL - triple sulphonamide suspension 0.5 g/5
mL; N = 80
Tx 2 - ampicillin 250 mg/5 mL; N = 36
Tx 3 - triple sulphonamide suspension 0.5 g/5 mL; N = 23
Tx 4 - erythromycin estolate 125 mg/5 mL; N = 25
C 1 - placebo - equal parts acetaminophen (paracetamol) and chlorpheniramine maleate
syrup; N = 33
C 2 - placebo - 4 parts Kaopectate and 1 part acetaminophen (paracetamol, Tylenol)
plus food colouring; N = 83
Use of additional medication - all children received decongestive nose drops for 7
days; analgesics (paracetamol, children < 1 year: 120 mg suppository, > 1 year: 240 mg
suppository) was allowed
Outcomes Primary outcomes - (a) presence or absence of exudate while on medication; (b) bac-
teriological findings of the exudate when present; no patient-relevant outcomes were
described
At baseline and before treatment was started, the middle-ear exudate was aspirated. The
decision whether to collect exudate on the first repeat visit was made with no knowledge
of the drug regimen to which the patient had been assigned
Notes -
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Howie 1972 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Low risk Randomisation was performed by a collab-
orating pharmacist
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - not described
Blinding of participants and personnel
(performance bias)
Unclear risk Identical taste and appearance to amox-
icillin/clavulanate and placebo not de-
scribed
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up - not described
Kaleida 1991
Methods Randomised - yes, stratified randomisation, method of randomisation not described
Concealment of allocation - unclear, method not described
Double-blind - yes, blinding procedure not described
Intention-to-treat (ITT) - yes
Loss to follow-up - not described
Design - parallel
Participants N - 536 children (representing 1049 non-severe acute otitis media (AOM) episodes; 980
non-severe AOM episodes included for primary analysis)
Age - between 7 months and 12 years
Setting - secondary care: children’s hospital and a private paediatric practice in Pittsburgh
(USA)
Inclusion criteria - AOM based on presence of middle-ear effusion, as determined
otoscopically, in associationwith specified symptoms of acutemiddle-ear infection (fever,
otalgia or irritability), or signs of acute infection (erythema or white opacification, or
both, accompanied by fullness or bulging and impaired mobility), or both
Exclusion criteria - children who recently received antibiotics, who had potential com-
plicating or confounding conditions (e.g. eardrum perforation, asthma or chronic si-
nusitis)
Baseline characteristics - balanced
Interventions Children were enrolled for a 1-year period. At entry each child was assigned randomly
to a treatment regimen that specified consistent treatments for episodes of non-severe
and severe AOM based on severity of otalgia and the presence of fever (> 39 °C orally
or > 39.5 °C rectally within the 24-hour period before presentation)
Non-severe AOM episodes were treated with:
Tx - amoxicillin 40 mg/kg/day 3 times daily for 14 days; N = 522 (N = 488 included in
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Kaleida 1991 (Continued)
primary analysis)
C - placebo for 14 days; N = 527 (N = 492 included in primary analysis)
Severe AOM episodes in children aged < 2 years were treated with:
Tx 1 - amoxicillin 40 mg/kg/day 3 times daily for 14 days
Tx 2 - amoxicillin 40 mg/kg/day 3 times daily for 14 days and myringotomy
Severe AOM episodes in children aged ≥ 2 years were treated with:
Tx 1 - amoxicillin 40 mg/kg/day 3 times daily for 14 days
Tx 2 - amoxicillin 40 mg/kg/day 3 times daily for 14 days and myringotomy
Tx 3 - placebo and myringotomy
Outcomes Primary outcome - initial treatment failure: in non-severe episodes this was the case
when either otalgia, fever or both was present more than 24 hours after treatment was
initiated and when 48 hours or more after initial treatment was initiated the child’s
temperature reached 38 °C orally or 38.5 °C rectally or an otalgia score of ≥ 6 was
present
Secondary outcomes - (a) recurrent AOM defined as the development of AOM 15 days
or more after the initiation of treatment for a preceding episode, (b) new episodes of
otitis media with effusion defined by otoscopy and tympanometry findings
After initial visits, childrenwere followedupby telephone to identify thosewith persistent
symptoms and children younger than 2 years of age were re-examined within 48 to 72
hours
Follow-up visits were scheduled routinely after 2 and 6 weeks after initial treatment and
monthly thereafter
Notes We included only the non-severe AOM episodes in this review (N = 1049 of which 980
were included for primary analysis); children experiencing non-severe AOM episodes
were randomly allocated to either antibiotics or placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk Method not described
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Identical taste and appearance to amoxi-
cillin and placebo not described
Incomplete outcome data (attrition bias) Unclear risk Follow-up/exclusion of non-
severe episodes for short-term outcome -
treatment: N = 34 (7%) and placebo: N =
35 (7%). Reasons not described
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Laxdal 1970
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - unclear; method not described
Double-blind - no; open-label study, investigators not blinded
Intention-to-treat (ITT) - unclear
Loss to follow-up - not described
Design - parallel
Participants N - 142 children
Age - between 0 to 15 years
Setting - secondary care (private paediatric clinic) in Saskatoon (Canada)
Inclusion criteria - at least 1 eardrum had to show redness and loss of landmarks
Exclusion criteria - predominant respiratory symptoms, if allergy appeared to be a
significant factor or if rupture of the eardrum had occurred
Baseline characteristics - not described
Interventions Tx 1 - penicillin G 250 mg/m2/day 4 times daily (approximately 33 mg/kg/day) for at
least 7 days; N = 45
Tx 2 - ampicillin 250 mg/m2/day 4 times daily (approximately 33 mg/kg/day) for at
least 7 days; N = 49
C - symptomatic therapy (Auralgan ear drops, acetylsalicylic acid, decongestive nose
drops); N = 48
Use of additional medication - children in treatment groups also received symptomatic
therapy as required
Outcomes Primary outcomes - (a) treatment failure (i.e. either deterioration or no improvement
observed at day 7) (b) relapses
Results were evaluated at 7 days, except in cases where the ear inflammation was severe
and the child appeared sufficiently ill (toxic) to warrant further examination 24 to 48
hours after treatment initiation
Children in the control group were subjected to very close scrutiny, especially during
the first 48 hours and particularly when severe involvement was evident (high risk of
detection bias)
Notes Open-label trial comparing immediate antibiotics (penicillin G and ampicillin) versus
expectant observation
It was unclear whether otalgia played an important role in the definition of treatment
failure
Data on relapses: N = 126 included in analysis, no crude numbers for separate treatment
groups provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk Not described
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Laxdal 1970 (Continued)
Other bias High risk ITT analysis - unclear, baseline character-
istics - not described, high risk of detec-
tion bias due to different follow-up strate-
gies between treatment groups
Blinding of participants and personnel
(performance bias)
Unclear risk Open-label trial, outcome assessment not
blinded
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up - not described for short-
term outcome. Loss to follow-up for long-
term outcome (acute otitis media (AOM)
relapses) -N=16 (11%), no crude numbers
of separate treatment groups provided
Le Saux 2005
Methods Randomised - yes, computer-generated randomisation sequence
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 531 children (N = 512 children included in analysis; N = 19 were excluded post hoc
due to inappropriate randomisation (N = 4) or alternative clinical diagnosis (N = 15))
Age - between 6 months and 5 years
Setting - secondary care: emergency department in Ottawa (Canada)
Inclusion criteria - new onset (< 4 days) of symptoms referable to the upper respiratory
tract and either ear pain or fever (> 38 °C). In addition, all patients had to have evidence
of middle-ear effusion, defined by≥ 2 of the following signs: opacity, impaired mobility
on the basis of pneumatic otoscopy and redness or bulging (or both) of the tympanic
membrane
Exclusion criteria - antibiotic treatment < 2 weeks prior to randomisation, contraindi-
cation to amoxicillin or penicillin or sensitivity to ibuprofen or aspirin, presence of otor-
rhoea, co-morbid disease such as sinusitis or pneumonia, prior middle-ear surgery, place-
ment of a ventilation tube, history of recurrent acute otitis media (more than 4 episodes
in 12 months), compromised immunity, craniofacial abnormalities, or any chronic or
genetic disorder
Baseline characteristics - balanced
Interventions Tx - amoxicillin suspension (60 mg/kg) 3 times daily for 10 days; N = 258 (N = 253
included in analysis for day 3)
C - matching placebo for 10 days; N = 254 (N = 246 included in analysis for day 3)
Use of additional medication - parents were given a 5-day supply of antipyretic and
analgesic medication in the form of ibuprofen suspension as required for pain or fever
and a 48-hour supply of codeine elixir to be given as required for pain and fever
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Le Saux 2005 (Continued)
Outcomes Primary outcome - clinical resolution of symptoms, defined as absence of receipt of an
antimicrobial (other than amoxicillin in the treatment group) at any time during the 14-
day period. The initiation of antimicrobial therapywas based on persistence or worsening
of symptoms, fever or irritability associated with otoscopic signs of unresolving AOM,
or development of symptoms indicative for mastoiditis or invasive disease
Secondary outcomes - (a) presence of symptoms (i.e. fever, pain, irritability, vomiting,
activity level) on days 1, 2 and 3; (b) number of analgesic doses, codeine doses on days
1, 2 and 3; (c) occurrence of any rash or diarrhoea in the 14 days after randomisation;
(d) presence of middle-ear effusion assessed by tympanometry at 1 and 3 months after
diagnosis
The parents were contacted on days 1, 2 and 3 after randomisation and once between
day 10 and day 14 for administration of a standard questionnaire. If the parents or re-
search assistant felt that the symptoms were not improving or were worsening, a med-
ical reassessment was advised and the child was seen by a physician in the emergency
department or clinic or by the paediatrician
The child was clinically assessed at 1 month and 3 months after randomisation to deter-
mine the number of subsequent episodes of acute otitis media (AOM) and to undergo
tympanometry
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence stratified by study centre and age
using random-permuted blocks of sizes 4
and 6
Allocation concealment (selection bias) Low risk Randomisation sequence was kept under
secure conditions and was accessible only
by the trial pharmacist
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Low risk Placebo was similar to amoxicillin with re-
gard to appearance and taste and was dis-
pensed in identical opaque bottles, which
were numbered sequentially
Incomplete outcome data (attrition bias) Low risk Loss to follow-up at day 3 - treatment: N
= 5 (2%) and placebo: N = 8 (3%)
40Antibiotics for acute otitis media in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Little 2001
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - adequate
Double-blind - no; open-label study, investigators not blinded
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 315 children (N = 285 children included in analysis)
Age - between 6 months and 10 years
Setting - general practice; 42 general practitioners in 3 health authorities in south-west
England
Inclusion criteria - acute otalgia and otoscopic evidence of acute inflammation of the
eardrum (dullness or cloudiness with erythema, bulging or perforation). When children
were too young for otalgia to be specifically documented from their history (under 3
years old) then otoscopic evidence alone was a sufficient entry criterion
Exclusion criteria - otoscopic appearances consistent with crying or a fever alone (pink
drum alone), appearances and history more suggestive of otitis media with effusion and
chronic suppurative otitis media, serious chronic disease (such as cystic fibrosis, valvular
heart disease), use of antibiotics < 2weeks prior to randomisation, previous complications
(septic complications, hearing impairment) and if the child was unwell to be left to wait
and see (e.g. high fever, floppy, drowsy, not responding to antipyretics)
Baseline characteristics - balanced
Interventions Tx - immediate treatment with antibiotics: amoxicillin syrup 125 mg/5mL 3 times daily
for 7 days (children who were allergic to amoxicillin received erythromycin 125 mg/5
mL 4 times daily; N = 151 (N = 135 included in analysis)
C - similar antibiotics were prescribed but parents were asked to wait for 72 hours before
considering using the prescription. Parents were instructed that if their child still had
substantial otalgia or fever after 72 hours, had discharge for > 10 days or was not starting
to get better then they should collect the antibiotic prescription that was left at the
practice; N = 164 (N = 150 included in analysis)
Use of additional medication - for both groups doctors emphasised the importance of
paracetamol in full doses for relief of pain and fever
Outcomes Primary outcomes - (a) duration of symptoms (i.e. earache, ear discharge, night distur-
bance, crying); (b) daily pain score; (c) episodes of distress; (d) spoons of paracetamol
used; (e) use of antibiotics
Doctors were asked to provide information on days of illness, physical signs and antibiotic
prescribing; parents were asked to complete a daily symptom diary
Notes Open-label trial comparing immediate versus delayed antibiotic prescription (prescrip-
tion provided but advised to fill only if symptoms did not improve or worsened)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
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Little 2001 (Continued)
Allocation concealment (selection bias) Low risk Sealed, numbered, opaque envelopes
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Open-label trial, outcome assessment not
blinded
Incomplete outcome data (attrition bias) Low risk Loss to follow-up/exclusion from analysis
(intervention ineffective, did not use an-
tibiotics or did not delay) - treatment: N =
16 (12%) and placebo: N = 14 (9%); com-
parison of the baseline information for the
3 types of responders (those who provided
diaries, those who gave information by tele-
phone and those from whom no diary in-
formation could be collected) revealed no
evidence of significant bias between treat-
ment groups or between patients by age or
severity of symptoms
McCormick 2005
Methods Randomised - yes, computer-generated randomisation sequence
Concealment of allocation - unclear; method not described
Double-blind - no, open-label trial, investigators blinded, parents not blinded
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 223 children (N = 218 children included in analysis at day 12)
Age - between 6 months and 12 years
Setting - secondary care: paediatric clinic of University of Texas Medical Branch (USA)
Inclusion criteria - children were required to have (a) symptoms of ear infection; (b)
otoscopic evidence of acute otitis media (AOM), including middle-ear effusion; (c) non-
severe AOM
Exclusion criteria - co-morbidity requiring antibiotic treatment, anatomic defect of ear
or nasopharynx, allergy to study medication, immunologic deficiency, major medical
condition and/or indwelling ventilation tube or draining otitis in the affected ear(s)
Baseline characteristics - balanced
Interventions Tx - immediate treatment with antibiotics: oral amoxicillin 90 mg/kg/day twice daily
for 10 days; N = 112 (N = 110 included in analysis at day 12)
C - expectant observation: no immediate antibiotics; N = 111 (N = 108 included in
analysis at day 12)
Children in the control group with AOM failure or recurrence received oral amoxicillin
90mg/kg/day; children inTx groupwithAOMfailure or recurrence received amoxicillin-
clavulanate (90 mg/kg/day of amoxicillin component)
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McCormick 2005 (Continued)
Use of additional medication - all parents received saline nose drops and/or cerumen-
removal drops (if needed), ibuprofen and over-the-counter decongestant/antihistamine
to be given as needed
Outcomes Primary outcomes - (a) parent satisfaction with AOM care; (b) resolution of AOM
symptoms after treatment, including number of doses of symptom medication given;
(c) AOM failure (days 0 to 12) or recurrence (days 13 to 30) defined as attending to
the paediatrician clinic with acute ear symptoms, an abnormal tympanic membrane, or
an AOM severity score higher than that at enrolment; (d) nasopharyngeal carriage of
Streptococcus pneumoniae strains resistant to antibiotics
Secondary outcomes - (a) minor adverse events caused by medication (e.g. allergy,
diarrhoea and candidal infection); (b) serious AOM-related adverse events (e.g. invasive
pneumococcal disease, mastoiditis, bacteraemia, meningitis, perforation of the tympanic
membrane, hospitalisation and emergency ear surgery; (c) parent-child quality of life
measures related to AOM
Parents were instructed to complete a symptom diary from day 1 to 10 and a satisfaction
questionnaire on day 12 and day 30; routine follow-up appointments for data collection
were scheduled for day 12 and day 30. Patient-initiated visits were scheduled on request
by the parents for children who seemed to not be responding to treatment
Notes Investigator-blinded trial comparing immediate antibiotic prescribing versus expectant
observation (no prescription provided)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Method not described
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Investigator-blinded study, parents not
blinded
Incomplete outcome data (attrition bias) Low risk Loss to follow-up at day 12 - treatment: N
= 2 (2%) and expectant observation: N = 3
(3%)
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Mygind 1981
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - reasons described, unclear from which treatment group patients
were excluded
Design - parallel
Participants N - 158 children (N = 149 included in analysis)
Age - between 1 and 10 years
Setting - general practice and secondary care: confirmation of diagnosis and trial recruit-
ment were done by otorhinolaryngologists in Copenhagen (Denmark)
Inclusion criteria - earache for 1 to 24 hours. The diagnosis was made if the child cried
because of pain and if the tympanic membrane appeared to be red and inflamed
Exclusion criteria - antibiotic treatment < 4 weeks prior to randomisation, other treat-
ment apart from acetylsalicylic acid already commenced, secretion in the external ear, sus-
pected chronic otitis media, treatment for secretory otitis media within last 12 months,
concurrent disease (e.g. pneumonia or severe tonsillitis), suspected penicillin allergy
Baseline characteristics - balanced
Interventions Tx - penicillin 50 mg/mL 4 times daily; children aged 1 to 2 years: 10 mL daily, children
between 3 and 5 years: 20 mL daily, children between 6 and 10 years: 30 mL daily for
7 days; N = ? (N = 72 included in analysis)
C - placebo for 7 days; N = ? (N = 77 included in analysis)
Use of additional medication - acetylsalicylic acid tablets (maximum of 50 mg/kg/day
for 3 days) were supplied as the only supplementary treatment permitted
Outcomes Main outcomes: (a) mean symptoms (i.e. pain, fever) scores; (b) number of analgesic
tables used; (c) contralateral otitis; (d) spontaneous perforation of tympanic membrane;
(e) mean number of days of otorrhoea; (f ) tympanometry results at 1 week, 4 weeks and
3 months
Initial visits were performed at home: otoscopy and bacterial culture from nasopharynx
were performed
Score cards were given to parents
Follow-up visits at hospital at day 2 to 3, day 7, week 4 and week 12. If supplementary
treatmentwas required at day 2 to 3, thenmyringotomywas performed. If supplementary
treatment was required at day 7, then amoxicillin was given
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Low risk Randomisation performed by pharmaceu-
tical company. Penicillin and placebo were
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supplied in coded bottles to study person-
nel
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Identical taste and appearance to amoxi-
cillin and placebo not described
Incomplete outcome data (attrition bias) Unclear risk Patients not included in analysis - N =
9 (6%). Reasons described, unclear from
which treatment group patients were ex-
cluded
Neumark 2007
Methods Randomised - yes, Internet-based random number generator
Concealment of allocation - unclear; method not described
Double-blind - no, open-label trial
Intention-to-treat (ITT) - unclear
Loss to follow-up - reasons described, unclear from which treatment group patients
were excluded
Design - parallel
Participants N - 186 children (N = 179 patients were included in analysis; 7 patients were excluded
due to non-compliance with protocol)
Age - between 2 and 16 years
Setting - general practice: 32 healthcare centres and 72 general practitioners in Sweden
Inclusion criteria - acute otitis media (AOM) was based on direct inspection of the
eardrum by pneumatic otoscope or preferably an aural microscope. Findings had to
include a bulging, red eardrum displaying reduced mobility
Exclusion criteria - perforation of the eardrum, chronic ear conditions or impaired
hearing, previous adverse reactions to penicillin, concurrent disease that should be treated
with antibiotics, recurrent AOM (3 or more AOM episodes during the past 6 months)
, children with immunosuppressive conditions, genetic disorders and mental disease or
retardation
Baseline characteristics - balanced
Interventions Tx - immediate treatment with antibiotics: phenoxymethylpenicillin 25 mg/kg twice
daily for 5 days; N = 92
C - expectant observation: no immediate antibiotics; N = 87
The guardians received written information about how to act if the condition did not
improve or got worse within 3 days after randomisation
Use of additional medication - symptomatic treatment with paracetamol or non-
steroidal anti-inflammatory drugs (NSAIDs), drugs reducing the swelling of the nasal
mucosa (e.g. decongestive nose drops) and nasal steroids were allowed
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Neumark 2007 (Continued)
Outcomes Primary outcomes - (a) pain at day 0, 1, 2 and 3 to 7; (b) use of analgesics at day 0, 1,
2, 3, 4 to 7; (c) fever > 38 °C at day 0, 1, 2 and 3 to 7; (d) subjective recovery at day 14
and 3 months; (e) perforations at 3 months; (f ) serous otitis media at 3 months
All participants were asked to complete a symptom diary for 7 days; a nurse telephoned
all participants after approximately 14 days to supplement the information in the diary
and to register all acute contacts that had occurred during the first week of treatment; the
final follow-up was performed after 3 months to register perforations and serous otitis
media
Notes Open-label trial comparing immediate antibiotic prescribing versus expectant observa-
tion (no prescription provided but advice on what to do if symptoms did not improve
or worsened)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Internet-based random number generator
Allocation concealment (selection bias) Unclear risk Method not described
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Open-label trial, outcome assessment not
blinded
Incomplete outcome data (attrition bias) Unclear risk Patients not included in analysis - N =
7 (4%). Reasons described, unclear from
which treatment group patients were ex-
cluded
Spiro 2006
Methods Randomised - yes, computer-assisted randomisation
Concealment of allocation - adequate
Double-blind - no, open-label study, investigators blinded
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 283 children (N = 265 children included in analysis at days 4 to 6)
Age - between 6 months and 12 years
Setting - secondary care: paediatric emergency department of Yale-NewHaven Hospital
in New Haven (USA)
Inclusion criteria - the diagnosis of acute otitis media (AOM) was made at the discre-
tion of the clinician according to the diagnostic criteria in the evidence-based guideline
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published in Pediatrics 2004
Exclusion criteria - presence of additional intercurrent bacterial infection such as pneu-
monia, if the patient appeared to be “toxic” as determined by the clinician, hospitalisa-
tion, immunocompromised children, antibiotic treatment < 1 week prior to randomi-
sation, children who had either myringotomy or a perforated tympanic membrane, un-
certain access to medical care (e.g. no telephone access), primary language of parents was
neither English nor Spanish, previous enrolment in the study
Baseline characteristics - balanced
Interventions Tx - immediate treatment with antibiotics; N = 145 (N = 133 included in analysis at
days 4 to 6)
C - participants randomised to delayed prescription were given written and verbal in-
structions “not to fill the antibiotic prescription unless your child either is not better or
is worse 48 hours (2 days) after today’s visit”; N = 138 (N = 132 included in analysis at
days 4 to 6)
Use of additional medication - all participants received complimentary bottles of
ibuprofen suspension (100 mg/5 mL) and analgesic ear drops
Outcomes Primary outcome -proportionof each group that filled the prescription for an antibiotic.
This was defined by whether the parent filled the prescription within 3 days of enrolment
and was determined by the response to this question at the interview at day 4 to 6
Secondary outcomes - (a) clinical course of the illness; (b) adverse effects ofmedications;
(c) days of school or work missed; (d) unscheduled medical visits; (e) comfort of parents
with management of AOM without antibiotics for future episodes
2 trained research assistants blinded to group assignment conducted standardised, struc-
tured telephone interviews with the parents at day 4 to 6, day 11 to 14, day 30 and day
40 after enrolment
Notes Investigator-blinded study comparing immediate versus delayed antibiotic prescribing
(prescription provided and advised to fill only if symptoms worsen or do not improve)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-assisted randomisation
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Unclear risk Investigator-blinded study, parents not
blinded
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up at day 4 to 6 treatment:
N = 12 (8%) and expectant observation: N
= 6 (4%)
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Tapiainen 2014
Methods Randomised - yes, block randomisation, computerised randomisation list
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 84 children (N = 84 children included in analysis at 8 weeks)
Age - between 6 months and 15 years
Setting - primary and secondary care: children in day care centres attending an AOM
prevention trial at the Department of Pediatrics, Oulu University Hospital and children
visiting the City of Oulu Health Care Center and Mehiläinen Pediatric Private Practice,
Oulu (Finland)
Inclusion criteria - acute symptomsof respiratory infection and/or ear-related symptoms
and signs of tympanic membrane inflammation together with middle-ear effusion at
pneumatic otoscopy performed by a study physician
Exclusion criteria - ventilation tubes (grommets), AOM complication, amoxicillin al-
lergy, Down syndrome, congenital craniofacial abnormality and immunodeficiency
Baseline characteristics - balanced
Interventions Tx - amoxicillin-clavulanate for 7 days (amoxicillin 40 mg/kg/day divided into 2 daily
doses); N = 42 (N = 42 included in analysis)
C - matching placebo in 2 doses for 7 days; N = 42 (N = 42 included in analysis)
Use of additional medication - not described
Outcomes Primary outcome - time middle-ear effusion disappearance defined as a normal tym-
panogram finding (A curve) from both ears on 2 consecutive measurement days (either
at home or at the study clinic)
Secondary outcomes - (a) time to improved tympanogram findings (i.e. A or C curve)
from both ears; (b) time to normal pneumatic otoscopy or otomicroscopy findings from
both ears; (c) proportions of children with persistent middle-ear effusion on days 7, 14
and 60; (d) disappearance of pain; (e) disappearance of fever; (f ) use of pain medication;
(g) possible adverse effects of antimicrobial treatment
Children were examined by the study physician with pneumatic otoscopy or otomi-
croscopy and tympanometry at study entry, after 3 and 7 days, and then weekly until
both ears were healthy according to pneumatic otoscopy or otomicroscopy
Families were trained to perform tympanometry using a handheld tympanometer for
daily follow-up at home
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation, computerised ran-
domisation list
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Allocation concealment (selection bias) Low risk Randomisation list was kept in the phar-
macy, which delivered the study drugs to
the families according to the consecutive
study number
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Low risk Bottles containing amoxicillin-clavulanate
or placebo were indistinguishable, dosing
was similar in both groups and placebo
mixture was flavoured and sweetened to re-
semble the taste of amoxicillin-clavulanate
Incomplete outcome data (attrition bias) Low risk All children were included in the analysis
Thalin 1985
Methods Randomised - yes, block randomisation, method of random sequence generation not
described
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - described
Design - parallel
Participants N - 293 children (N = 293 children included in analysis)
Age - between 2 and 15 years
Setting - secondary care: department of otorhinolaryngology in Halmstad (Sweden)
Inclusion criteria - purulent acute otitis media (AOM) (no further criteria described)
Exclusion criteria - antibiotic treatment or AOM episode < 4 weeks prior to randomi-
sation, suspected penicillin allergy, presence of ventilation tubes, sensorineural hearing
loss, existence of concomitant infection for which antibiotic treatment was required and
chronic diseases
Baseline characteristics - not described
Interventions Tx - phenoxymethyl penicillin 50 mg/kg/day twice daily for 7 days; N = 159 (N = 159
included in analysis)
C - matching placebo in 2 doses for 7 days; N = 158 (N = 158 included in analysis)
Use of additional medication - all children were given nose drops containing oxymeta-
zoline chloride and, if needed, analgesics (paracetamol)
Outcomes Primary outcome - treatment failure (defined as remaining non-negligible symptoms
such as pain and fever, insufficient resolution of infectious signs during treatment period
of 7 days, or both
Secondary outcomes - (a) resolution of symptoms over time; (b) AOM relapses; (c)
tympanometry, audiometry, or both, results at 4 weeks
The children were examined at day 0, days 3 to 4, days 8 to 10 and at 4 weeks
49Antibiotics for acute otitis media in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Thalin 1985 (Continued)
Parents were instructed to record symptoms (i.e. temperature, otalgia, discharge from
ear and consumption of supplied symptomatic drugs)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block randomisation, method of random
sequence generation not described
Allocation concealment (selection bias) Low risk Randomisation list was kept by the clinical
pharmacologist of the hospital and not dis-
closed to the investigators until the clinical
trial was completed
Other bias Unclear risk ITT analysis - unclear; baseline character-
istics - not described
Blinding of participants and personnel
(performance bias)
Low risk Placebo with same taste and appearance as
penicillin
Incomplete outcome data (attrition bias) Low risk No children lost to follow-up for primary
analysis
Tähtinen 2011
Methods Randomised - yes, computerised random number generator with block length of 10
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - yes
Loss to follow-up - described
Design - parallel
Participants N - 322 children (N = 319 children were included in analysis)
Age - between 6 months and 3 years
Setting - general practice: healthcare centre of Turku (Finland)
Inclusion criteria - acute otitis media (AOM) based on 3 criteria: (a) middle-ear fluid
had to be detected by means of pneumatic otoscopic examination that showed at least
2 of the following tympanic membrane findings: bulging position, decreased or absent
mobility, abnormal colour or opacity not due to scarring, or air fluid interfaces; (b) at
least 1 of the following acute inflammatory signs in the tympanic membrane had to
be present: distinct erythematous patches or streaks or increased vascularity over full,
bulging, or yellow tympanic membrane; (c) presence of acute symptoms such as fever,
otalgia or respiratory symptoms
Exclusion criteria - ongoing antibiotic treatment; AOM with spontaneous perforation
of the tympanic membrane; systemic or nasal steroid therapy within 3 preceding days;
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antihistamine, oseltamivir or a combination therapywithin 3 preceding days; contraindi-
cation to penicillin or amoxicillin; presence of ventilation tube; severe infection requiring
antibiotic treatment; documented Epstein-Barr virus infection within 7 preceding days;
Down’s syndrome or other condition affecting middle-ear diseases; known immunode-
ficiency
Baseline characteristics - balanced
Interventions Tx - amoxicillin-clavulanate 40-5.7 mg/kg daily in 2 doses for 7 days; N = 162 (N = 161
included in analysis)
C - matching placebo in 2 doses for 7 days; N = 160 (N = 158 included in analysis)
Use of additional medication - the use of analgesics and antipyretic agents was en-
couraged and the use of analgesic ear drops and decongestive nose drops or sprays was
allowed
Outcomes Primary outcome - time to treatment failure (i.e. a composite endpoint consisting
of 6 independent components: (a) no improvement in overall condition at day 2, (b)
worsening of the child’s overall condition at any time, (c) no improvement in otoscopic
signs at day 7, (d) perforation of tympanic membrane at any time, (e) severe infection (e.
g. mastoiditis or pneumonia) necessitating systemic open-label antimicrobial treatment
at any time, (f ) any other reason for stopping the study drug at any time
Secondary outcomes - assessed by study physician - (a) time to the initiation of rescue
treatment; (b) time to development of contralateral AOM; - diary symptom assessment;
(c) resolution of symptoms; (d) use of analgesics
Parents were given a diary to record symptoms, doses of study drugs and any other
medications and adverse events
First visit after enrolment (= day 0) was scheduled at day 2. End-of-treatment visit was
scheduled at day 7
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generator
with block length of 10
Allocation concealment (selection bias) Low risk Concealment of allocation by the pharma-
cist (independent to trial team) by labelling
the identical opaque study drug contain-
ers with allocation numbers; allocation list
was kept at the paediatric infectious disease
ward behind locked doors
Other bias Low risk ITT analysis - yes, baseline characteristics -
balanced
Blinding of participants and personnel
(performance bias)
Low risk Placebo with same taste and appearance as
amoxicillin-clavulanate
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Tähtinen 2011 (Continued)
Incomplete outcome data (attrition bias) Low risk Loss to follow-up - treatment: N = 1 (1%)
and placebo: N = 2 (1%)
van Buchem 1981a
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - reasons not described, unclear from which treatment group patients
were excluded
Design - 2 x 2 factorial design
Participants N - 202 children (N = 171 children included in analysis; N = 31 were excluded from
the study)
Age - between 2 and 12 years
Setting - both general practice and secondary care: 12 general practitioners in or near
Tilburg (the Netherlands) recruited patients and referred them to 1 of the 3 otorhino-
laryngologists, which excluded those cases where there was disagreement with the diag-
nosis
Inclusion criteria - acute otitis media (AOM) was based on history and clinical picture
(i.e. diffuse redness, bulging of the eardrum, or both)
Exclusion criteria - antibiotic treatment < 2 weeks prior to randomisation, chronic otitis
or otitis media serosa, contraindication for antibiotic treatment
Baseline characteristics - balanced
Interventions Tx - sham myringotomy and amoxicillin 250 mg 3 times daily for 7 days; N = 47
C - sham myringotomy and matching placebo for 7 days; N = 40
Use of additional medication - all participants were allowed to use decongestive nose
drops and analgesic suppositories (i.e. children aged 2 to 7 years: acetylsalicylic acid 50
mg, phenacetin 50 mg, phenobarbitone 15 mg, codeine phosphate 2.5 mg, caffeine 1.
25 mg; children aged 8 to 12 years: acetylsalicylic acid 100 mg, phenacetin 100 mg,
phenobarbitone 30 mg, codeine phosphate 5 mg, caffeine 2.5 mg
Outcomes Main outcomes - (a) parent report of pain at day 0, 1 and 7; (b) otoscopic findings at
day 0, 1 and 7; (c) discharge from ear at day 1, 7 and 14; (d) mean temperature at day
0, 1 and 7; (e) AOM relapses at 6 months; (f ) audiogram findings after 4 and 8 weeks
Notes van Buchem 1981a is the 2 arms without myringotomy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
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van Buchem 1981a (Continued)
Allocation concealment (selection bias) Low risk Randomisation performed by otorhino-
laryngologists; general practitioner and
parent/childwere outcome assessors and re-
mained blinded
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - balanced
Blinding of participants and personnel
(performance bias)
Low risk Sham myringotomy and placebo was simi-
lar with amoxicillin with regard to appear-
ance and taste
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up/exclusions - N = 31
(15%). Reasons not described
van Buchem 1981b
Methods Randomised - yes, method of randomisation not described
Concealment of allocation - adequate
Double-blind - yes
Intention-to-treat (ITT) - unclear
Loss to follow-up - reasons not described, unclear from which treatment group patients
were excluded
Design - 2 x 2 factorial design
Participants N - 202 children (N = 171 children included in analysis; N = 31 were excluded from
the study)
Age - between 2 and 12 years
Setting - both general practice and secondary care: 12 general practitioners in or near
Tilburg (the Netherlands) recruited patients and referred them to 1 of the 3 otorhino-
laryngologists who excluded those cases where there was disagreement with the diagnosis
Inclusion criteria - acute otitis media (AOM) was based on history and clinical picture
(i.e. diffuse redness, bulging of the eardrum, or both)
Exclusion criteria - antibiotic treatment < 2 weeks prior to randomisation, chronic otitis
or otitis media serosa, contraindication for antibiotic treatment
Baseline characteristics - balanced
Interventions Tx - myringotomy and amoxicillin 250 mg 3 times daily for 7 days; N = 48
C - myringotomy and matching placebo for 7 days; N = 36
Use of additional medication - all participants were allowed to use decongestive nose
drops and analgesic suppositories (i.e. children aged 2 to 7 years: acetylsalicylic acid 50
mg, phenacetin 50 mg, phenobarbitone 15 mg, codeine phosphate 2.5 mg, caffeine 1.
25 mg; children aged 8 to 12 years: acetylsalicylic acid 100 mg, phenacetin 100 mg,
phenobarbitone 30 mg, codeine phosphate 5 mg, caffeine 2.5 mg
Outcomes Main outcomes - (a) parent report of pain at day 0, 1 and 7; (b) otoscopic findings at
day 0, 1 and 7; (c) discharge from ear at day 1, 7 and 14; (d) mean temperature at day
0, 1 and 7; (e) AOM relapses at 6 months; (f ) audiogram findings after 4 and 8 weeks
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van Buchem 1981b (Continued)
Notes van Buchem 1981b is the 2 arms with myringotomy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Low risk Randomisation performed by otorhino-
laryngologists; general practitioner and
parent/childwere outcome assessors and re-
mained blinded
Other bias Unclear risk ITT analysis - unclear, baseline character-
istics - balanced
Blinding of participants and personnel
(performance bias)
Low risk Sham myringotomy and placebo was simi-
lar with amoxicillin with regard to appear-
ance and taste
Incomplete outcome data (attrition bias) Unclear risk Loss to follow-up/exclusions - N = 31
(15%). Reasons not described
AOM: acute otitis media
AOM-SOS: otitis media - severity of symptoms
C: control
ITT: intention-to-treat
Tx: treatment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arguedas 2011 No comparison of antibiotic to placebo or expectant observation: trial comparing single-dose, extended-release
azithromycin versus a 10-day regimen of amoxicillin/clavulanate
Casey 2012 No comparison of antibiotic to placebo or expectant observation: trial comparing high-dose amoxicillin/clavu-
lanate versus cefdinir
Chaput 1982 Short versus long course of therapy
Engelhard 1989 No comparison of antibiotic to placebo; the 3 arms were Augmentin, myringotomy, or both
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(Continued)
Liu 2011 No comparison of antibiotic to placebo or expectant observation: trial comparing single oral doses azithromycin
in extended-release versus immediate-release formulations
Ostfeld 1987 Non-randomised study
Rudberg 1954 Non-randomised study: assigned “randomly” based on case number but then allowed to change groups
Ruohola 2003 Conducted in children with ventilation tubes
Sarrell 2003 No comparison of antibiotic to placebo. Method of randomisation not provided and groups appear to be
unbalanced at baseline
Tähtinen 2012 Secondary analysis of placebo-controlled trial. This study included the total group of children allocated to
immediate antimicrobial treatment (N = 161) and a subgroup of children from the placebo group that received
delayed antibiotics (N = 53). As a consequence, comparability of prognosis achieved through randomisation is
violated, producing groups of children that are incomparable, which may lead to biased effect estimates
van Buchem 1985 Non-randomised study
Characteristics of ongoing studies [ordered by study ID]
ACTRN12608000424303
Trial name or title Antibiotics for asymptomatic acute otitis media
Methods Double-blind, placebo-controlled randomised clinical trial
Participants Aboriginal children aged between 6 and 30 months diagnosed with asymptomatic acute otitis media defined
as a bulging tympanic membrane without associated symptoms (including ear pain, fever or ear discharge) at
the time of diagnosis
Interventions Azithromycin 30 mg/kg divided into 2 doses or placebo for 7 days
Outcomes Primary outcome - proportion of children with a bulging tympanic membrane or ear discharge or withdrawn
due to complications or side effects at 14 days (all children who are lost to follow-up are considered clinical
failures)
Secondary outcomes - (a) proportion of children with unresolved bulging at 7 and 30 days; (b) proportion
of children with a bulging tympanic membrane or ear discharge or withdrawn due to complications or side
effects at 7, 14 and 30 days (not including children who are lost to follow-up); (c) proportion of children who
develop an illness requiring additional medical treatment at 7, 14 and 30 days; (d) proportion of children
who develop an illness requiring cessation of prescribed antibiotics at 30 days; (e) proportion of children
who have no improvement in other conditions recorded, like skin sores and rhinosinusitis, at 7, 14 and 30
days; (f ) microbiological outcomes including carriage and antibiotic resistance of Streptococcus pneumoniae
and Haemophilus influenzae at 7, 14 and 30 days
Starting date March 2007
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ACTRN12608000424303 (Continued)
Contact information Menzies School of Health Research, PO Box 41096, Casuarina NT 0811, Australia
Notes ACTRN12608000424303
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Pain at 24 hours 6 1394 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.78, 1.01]
1.2 Pain at 2 to 3 days 7 2320 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.57, 0.86]
1.3 Pain at 4 to 7 days 8 1347 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.63, 0.91]
1.4 Pain at 10 to 12 days 1 278 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.17, 0.66]
2 Vomiting, diarrhoea or rash 8 2107 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.19, 1.59]
3 Abnormal tympanometry 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 2 to 4 weeks 7 2138 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.74, 0.90]
3.2 6 to 8 weeks 3 953 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.78, 1.00]
3.3 3 months 3 809 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.76, 1.24]
4 Tympanic membrane perforation 5 1075 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.18, 0.76]
5 Contralateral otitis (in unilateral
cases)
4 906 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.25, 0.95]
6 Late AOM recurrences 6 2200 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.78, 1.10]
Comparison 2. Immediate antibiotics versus expectant observation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Pain at 3 to 7 days 4 959 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.50, 1.12]
1.2 Pain at 11 to 14 days 1 247 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
2 Vomiting, diarrhoea or rash 2 550 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.24, 2.36]
3 Abnormal tympanometry at 4
weeks
1 207 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.78, 1.35]
4 Tympanic membrane perforation 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 AOM recurrences 1 209 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.74, 2.69]
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Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Pain.
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 1 Pain
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pain at 24 hours
Burke 1991 53/112 56/117 18.5 % 0.99 [ 0.75, 1.30 ]
Le Saux 2005 82/258 106/254 36.1 % 0.76 [ 0.60, 0.96 ]
Thalin 1985 62/159 62/158 21.0 % 0.99 [ 0.76, 1.31 ]
Ta¨htinen 2011 40/85 47/80 16.4 % 0.80 [ 0.60, 1.07 ]
van Buchem 1981a 13/47 11/40 4.0 % 1.01 [ 0.51, 1.99 ]
van Buchem 1981b 17/48 10/36 3.9 % 1.28 [ 0.67, 2.44 ]
Subtotal (95% CI) 709 685 100.0 % 0.89 [ 0.78, 1.01 ]
Total events: 267 (Antibiotics), 292 (Placebo)
Heterogeneity: Chi2 = 4.75, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Pain at 2 to 3 days
Appelman 1991 11/67 10/54 6.0 % 0.89 [ 0.41, 1.93 ]
Halsted 1968 17/62 7/27 5.3 % 1.06 [ 0.50, 2.25 ]
Kaleida 1991 19/488 38/492 20.6 % 0.50 [ 0.29, 0.86 ]
Le Saux 2005 43/253 53/246 29.2 % 0.79 [ 0.55, 1.13 ]
Mygind 1981 15/72 29/77 15.2 % 0.55 [ 0.32, 0.94 ]
Thalin 1985 16/159 25/158 13.6 % 0.64 [ 0.35, 1.14 ]
Ta¨htinen 2011 17/85 18/80 10.1 % 0.89 [ 0.49, 1.60 ]
Subtotal (95% CI) 1186 1134 100.0 % 0.70 [ 0.57, 0.86 ]
Total events: 138 (Antibiotics), 180 (Placebo)
Heterogeneity: Chi2 = 4.82, df = 6 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
3 Pain at 4 to 7 days
Burke 1991 20/111 29/114 18.0 % 0.71 [ 0.43, 1.18 ]
Damoiseaux 2000 69/117 89/123 54.5 % 0.82 [ 0.68, 0.98 ]
Mygind 1981 10/72 24/77 14.6 % 0.45 [ 0.23, 0.87 ]
Tapiainen 2014 0/42 7/42 4.7 % 0.07 [ 0.00, 1.13 ]
Thalin 1985 5/159 2/158 1.3 % 2.48 [ 0.49, 12.62 ]
0.001 0.01 0.1 1 10 100 1000
Antibiotics better Placebo better
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ta¨htinen 2011 7/85 2/80 1.3 % 3.29 [ 0.71, 15.39 ]
van Buchem 1981a 3/46 4/38 2.8 % 0.62 [ 0.15, 2.60 ]
van Buchem 1981b 5/48 4/35 2.9 % 0.91 [ 0.26, 3.15 ]
Subtotal (95% CI) 680 667 100.0 % 0.76 [ 0.63, 0.91 ]
Total events: 119 (Antibiotics), 161 (Placebo)
Heterogeneity: Chi2 = 11.65, df = 7 (P = 0.11); I2 =40%
Test for overall effect: Z = 3.05 (P = 0.0023)
4 Pain at 10 to 12 days
Hoberman 2011 10/139 30/139 100.0 % 0.33 [ 0.17, 0.66 ]
Subtotal (95% CI) 139 139 100.0 % 0.33 [ 0.17, 0.66 ]
Total events: 10 (Antibiotics), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
0.001 0.01 0.1 1 10 100 1000
Antibiotics better Placebo better
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Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Vomiting, diarrhoea or rash.
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 2 Vomiting, diarrhoea or rash
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Burke 1991 53/114 36/118 17.1 % 1.52 [ 1.09, 2.13 ]
Damoiseaux 2000 20/117 12/123 5.7 % 1.75 [ 0.90, 3.42 ]
Hoberman 2011 49/144 36/147 17.2 % 1.39 [ 0.97, 2.00 ]
Le Saux 2005 43/235 47/240 22.5 % 0.93 [ 0.64, 1.36 ]
Mygind 1981 3/72 1/77 0.5 % 3.21 [ 0.34, 30.14 ]
Tapiainen 2014 9/42 2/42 1.0 % 4.50 [ 1.03, 19.60 ]
Thalin 1985 1/159 1/158 0.5 % 0.99 [ 0.06, 15.75 ]
Ta¨htinen 2011 105/161 73/158 35.6 % 1.41 [ 1.15, 1.73 ]
Total (95% CI) 1044 1063 100.0 % 1.38 [ 1.19, 1.59 ]
Total events: 283 (Antibiotics), 208 (Placebo)
Heterogeneity: Chi2 = 8.16, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 4.35 (P = 0.000014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Antibiotics better Placebo better
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Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Abnormal tympanometry.
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 3 Abnormal tympanometry
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2 to 4 weeks
Appelman 1991 21/51 25/45 5.2 % 0.74 [ 0.49, 1.13 ]
Burke 1991 41/112 41/116 7.8 % 1.04 [ 0.73, 1.46 ]
Kaleida 1991 188/401 255/408 49.2 % 0.75 [ 0.66, 0.85 ]
Le Saux 2005 68/233 77/222 15.3 % 0.84 [ 0.64, 1.10 ]
Mygind 1981 23/72 25/77 4.7 % 0.98 [ 0.62, 1.57 ]
Tapiainen 2014 13/42 26/42 5.1 % 0.50 [ 0.30, 0.83 ]
Thalin 1985 65/159 65/158 12.7 % 0.99 [ 0.76, 1.29 ]
Subtotal (95% CI) 1070 1068 100.0 % 0.82 [ 0.74, 0.90 ]
Total events: 419 (Antibiotics), 514 (Placebo)
Heterogeneity: Chi2 = 10.01, df = 6 (P = 0.12); I2 =40%
Test for overall effect: Z = 4.18 (P = 0.000029)
2 6 to 8 weeks
Damoiseaux 2000 69/107 70/105 28.3 % 0.97 [ 0.80, 1.18 ]
Kaleida 1991 151/329 169/328 67.7 % 0.89 [ 0.76, 1.04 ]
Tapiainen 2014 2/42 10/42 4.0 % 0.20 [ 0.05, 0.86 ]
Subtotal (95% CI) 478 475 100.0 % 0.88 [ 0.78, 1.00 ]
Total events: 222 (Antibiotics), 249 (Placebo)
Heterogeneity: Chi2 = 4.81, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.92 (P = 0.054)
3 3 months
Burke 1991 20/111 31/111 31.9 % 0.65 [ 0.39, 1.06 ]
Le Saux 2005 58/228 47/210 50.3 % 1.14 [ 0.81, 1.59 ]
Mygind 1981 18/72 18/77 17.9 % 1.07 [ 0.61, 1.89 ]
Subtotal (95% CI) 411 398 100.0 % 0.97 [ 0.76, 1.24 ]
Total events: 96 (Antibiotics), 96 (Placebo)
Heterogeneity: Chi2 = 3.56, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.26 (P = 0.80)
0.01 0.1 1 10 100
Antibiotics better Placebo better
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Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 Tympanic membrane perforation.
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 4 Tympanic membrane perforation
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tapiainen 2014 0/42 0/42 Not estimable
Hoberman 2011 1/144 7/147 26.6 % 0.15 [ 0.02, 1.17 ]
Ta¨htinen 2011 1/161 5/158 19.4 % 0.20 [ 0.02, 1.66 ]
Burke 1991 0/114 2/118 9.4 % 0.21 [ 0.01, 4.26 ]
Mygind 1981 7/72 12/77 44.6 % 0.62 [ 0.26, 1.50 ]
Total (95% CI) 533 542 100.0 % 0.37 [ 0.18, 0.76 ]
Total events: 9 (Antibiotics), 26 (Placebo)
Heterogeneity: Chi2 = 2.59, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Antibiotics better Placebo better
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Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Contralateral otitis (in unilateral cases).
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 5 Contralateral otitis (in unilateral cases)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Burke 1991 29/98 33/102 36.1 % 0.91 [ 0.60, 1.38 ]
Hoberman 2011 13/161 29/158 30.9 % 0.44 [ 0.24, 0.81 ]
Mygind 1981 2/64 6/63 12.7 % 0.33 [ 0.07, 1.56 ]
Thalin 1985 4/130 17/130 20.3 % 0.24 [ 0.08, 0.68 ]
Total (95% CI) 453 453 100.0 % 0.49 [ 0.25, 0.95 ]
Total events: 48 (Antibiotics), 85 (Placebo)
Heterogeneity: Tau2 = 0.28; Chi2 = 8.79, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Antibiotics better Placebo better
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Analysis 1.6. Comparison 1 Antibiotics versus placebo, Outcome 6 Late AOM recurrences.
Review: Antibiotics for acute otitis media in children
Comparison: 1 Antibiotics versus placebo
Outcome: 6 Late AOM recurrences
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hoberman 2011 19/119 13/70 7.5 % 0.86 [ 0.45, 1.63 ]
Kaleida 1991 125/448 123/446 56.6 % 1.01 [ 0.82, 1.25 ]
Le Saux 2005 27/248 39/236 18.3 % 0.66 [ 0.42, 1.04 ]
Mygind 1981 19/72 21/77 9.3 % 0.97 [ 0.57, 1.65 ]
Thalin 1985 9/159 7/158 3.2 % 1.28 [ 0.49, 3.35 ]
van Buchem 1981a 9/92 10/75 5.1 % 0.73 [ 0.31, 1.71 ]
Total (95% CI) 1138 1062 100.0 % 0.93 [ 0.78, 1.10 ]
Total events: 208 (Antibiotics), 213 (Placebo)
Heterogeneity: Chi2 = 3.60, df = 5 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 2.1. Comparison 2 Immediate antibiotics versus expectant observation, Outcome 1 Pain.
Review: Antibiotics for acute otitis media in children
Comparison: 2 Immediate antibiotics versus expectant observation
Outcome: 1 Pain
Study or subgroup Antibiotics
Expectant
observa-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pain at 3 to 7 days
Little 2001 26/151 44/164 28.2 % 0.64 [ 0.42, 0.99 ]
McCormick 2005 24/102 38/98 28.3 % 0.61 [ 0.40, 0.93 ]
Neumark 2007 2/92 4/87 5.2 % 0.47 [ 0.09, 2.52 ]
Spiro 2006 89/133 85/132 38.4 % 1.04 [ 0.87, 1.24 ]
Subtotal (95% CI) 478 481 100.0 % 0.75 [ 0.50, 1.12 ]
Total events: 141 (Antibiotics), 171 (Expectant observation)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.28, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Pain at 11 to 14 days
Spiro 2006 75/123 83/124 100.0 % 0.91 [ 0.75, 1.10 ]
Subtotal (95% CI) 123 124 100.0 % 0.91 [ 0.75, 1.10 ]
Total events: 75 (Antibiotics), 83 (Expectant observation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 2.2. Comparison 2 Immediate antibiotics versus expectant observation, Outcome 2 Vomiting,
diarrhoea or rash.
Review: Antibiotics for acute otitis media in children
Comparison: 2 Immediate antibiotics versus expectant observation
Outcome: 2 Vomiting, diarrhoea or rash
Study or subgroup Antibiotics
Expectant
observa-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2001 31/135 22/150 45.4 % 1.57 [ 0.95, 2.57 ]
Spiro 2006 46/133 25/132 54.6 % 1.83 [ 1.20, 2.79 ]
Total (95% CI) 268 282 100.0 % 1.71 [ 1.24, 2.36 ]
Total events: 77 (Antibiotics), 47 (Expectant observation)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Immediate antibiotics versus expectant observation, Outcome 3 Abnormal
tympanometry at 4 weeks.
Review: Antibiotics for acute otitis media in children
Comparison: 2 Immediate antibiotics versus expectant observation
Outcome: 3 Abnormal tympanometry at 4 weeks
Study or subgroup Antibiotics
Expectant
observa-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McCormick 2005 55/108 49/99 100.0 % 1.03 [ 0.78, 1.35 ]
Total (95% CI) 108 99 100.0 % 1.03 [ 0.78, 1.35 ]
Total events: 55 (Antibiotics), 49 (Expectant observation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Immediate ab better Expectant obs better
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Analysis 2.4. Comparison 2 Immediate antibiotics versus expectant observation, Outcome 4 Tympanic
membrane perforation.
Review: Antibiotics for acute otitis media in children
Comparison: 2 Immediate antibiotics versus expectant observation
Outcome: 4 Tympanic membrane perforation
Study or subgroup Antibiotics
Expectant
observa-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neumark 2007 0/92 0/87 Not estimable
Total (95% CI) 92 87 Not estimable
Total events: 0 (Antibiotics), 0 (Expectant observation)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Immediate ab better Expectant obs better
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Analysis 2.5. Comparison 2 Immediate antibiotics versus expectant observation, Outcome 5 AOM
recurrences.
Review: Antibiotics for acute otitis media in children
Comparison: 2 Immediate antibiotics versus expectant observation
Outcome: 5 AOM recurrences
Study or subgroup Antibiotics
Expectant
observa-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McCormick 2005 20/109 13/100 100.0 % 1.41 [ 0.74, 2.69 ]
Total (95% CI) 109 100 100.0 % 1.41 [ 0.74, 2.69 ]
Total events: 20 (Antibiotics), 13 (Expectant observation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Immediate ab better Expectant obs better
A P P E N D I C E S
Appendix 1. Previous search
Several electronic databases were used to compile relevant published RCTs of antibiotic treatment of AOM in children. The Cochrane
Controlled Trials Register, MEDLINE and Current Contents were searched from 1966 to January 2000 by an expert librarian in
conjunction with one researcher, using combinations of “OTITIS MEDIA” and a search strategy described by (Dickersin 1994) for
optimally identifying controlled trials. In addition, titles in Index Medicus were checked from 1958 to 1965. The references of all
relevant retrieved trials were checked to identify other articles.
The search was updated in March 2003, and again in July 2008. We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2008, Issue 2), which contains the ARI Group’s Specialized Register; MEDLINE (1966 to June
week 4 2008); OLDMEDLINE (1958 to 1965); EMBASE (January 1990 to July 2008); and Current Contents (1966 to July 2008).
The bibliographies of relevant articles were checked. A forward search of relevant articles was conducted in Web of Science®.
The following search strategy was run onMEDLINE (Ovid) combined with terms from Phase 1 and 2 of the Cochrane highly sensitive
search strategy for identifying reports of RCTs (Lefebvre 2011). Modified terms were used to search the other databases:
MEDLINE (Ovid)
#1 exp Otitis Media/
#2 exp Otitis Media with Effusion/
#3 exp Otitis Media, Suppurative/
#4 glue ear.mp.
#5 otitis media.mp.
#6 OME.mp.
#7 AOM.mp.
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#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 exp Anti-Bacterial Agents/
#10 exp Drug Therapy/
#11 exp Anti-Infective Agents/
#12 antibiotic$.mp.
#13 #9 or #10 or #11 or #12
#14 #8 and #13
There were no language or publication restrictions.
Appendix 2. MEDLINE (Ovid) search strategy
1 exp Otitis Media/
2 otitis media.tw.
3 glue ear*.tw.
4 (middle ear adj5 (infect* or inflam*)).tw.
5 (ome or aom).tw.
6 or/1-5
7 exp Anti-Bacterial Agents/
8 Drug Therapy/
9 Anti-Infective Agents/
10 antibiotic*.tw.
11 antibacterial*.tw.
12 exp Ampicillin/
13 exp Cephalosporins/
14 exp Macrolides/
15 exp Penicillins/
16 (ampicillin* or cephalosporin* or macrolide* or penicillin* or amoxicillin* or amoxycillin* or cefdinir or cefpodoxime or cefuroxime
or azithromycin or clarithromycin or erythromycin*).tw,nm.
17 or/7-16
18 6 and 17
Appendix 3. Embase.com search strategy
18 #14 AND #17
17 #15 OR #16
16 random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR ’cross over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti
15 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
14 #4 AND #13
13 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
12 ampicillin*:ab,ti OR cephalosporin*:ab,ti OR macrolide*:ab,ti OR penicillin*:ab,ti OR amoxycillin*:ab,ti OR amoxicillin*:ab,ti
OR cefdinir*:ab,ti OR cefpodoxime*:ab,ti OR cefuroxime*:ab,ti OR
azithromycin*:ab,ti OR clarithromycin*:ab,ti OR erythromycin*:ab,ti
11 ’penicillin g’/exp
10 ’macrolide’/exp
9 ’cephalosporin derivative’/exp
8 ’ampicillin’/exp
7 antibiotic*:ab,ti OR antibacterial*:ab,ti
6 ’drug therapy’/de OR ’antiinfective agent’/de
5 ’antibiotic agent’/exp
4 #1 OR #2 OR #3
3 (’middle ear’ NEAR/5 (inflam* OR infect*)):ab,ti
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2 ’otitis media’:ab,ti OR ’glue ear’:ab,ti OR ’glue ears’:ab,ti OR ome:ab,ti OR aom:ab,ti
1 ’otitis media’/exp
Appendix 4. Current Contents search strategy
# 3 578 #2 AND #1
Databases=CM, LS Timespan=All Years
Lemmatization=On
# 2 528,401 Topic=(random* or placebo* or crossover* or “cross over” or allocat* or ((doubl* or singl*) NEAR/1 blind*)) OR
Title=(trial)
Databases=CM, LS Timespan=All Years
Lemmatization=On
# 1 2,624 Topic=(otitis or “glue ear” or (“middle ear” NEAR/3 (infect* or inflam*)) or ome or aom) ANDTopic=(antibiotic*
or antibacterial* or antiinfective* or ampicillin* or cephalosporin* or macrolide* or amoxicillin* or amoxycillin* or
penicillin* or cefdinir* or cefpodoxime* or cefuroxime* or azithromycin* or clarithromycin* or erythromycin*)
Databases=CM, LS Timespan=All Years
Lemmatization=On
Appendix 5. CINAHL search strategy
S30 S19 and S29
S29 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28
S28 (MH “Quantitative Studies”)
S27 TI placebo* or AB placebo*
S26 (MH “Placebos”)
S25 TI random* or AB random*
S24 (MH “Random Assignment”)
S23 TI (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*)
or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*)
S22 TI clinic* N1 trial* or AB clinic* N1 trial*
S21 PT clinical trial
S20 (MH “Clinical Trials+”)
S19 S7 and S18
S18 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17
S17 TI ( ampicillin* or cephalosporin* or macrolide* or amoxicillin* or amoxycillin* or penicillin* or cefdinir* or cefpodoxime* or
cefuroxime* or azithromycin* or clarithromycin* or erythromycin* ) or AB ( ampicillin* or cephalosporin* ormacrolide* or amoxicillin*
or amoxycillin* or penicillin* or cefdinir* or cefpodoxime* or cefuroxime* or azithromycin* or clarithromycin* or erythromycin* )
S16 (MH “Penicillins+”)
S15 (MH “Antibiotics, Macrolide+”)
S14 (MH “Cephalosporins+”)
S13 (MH “Ampicillin+”)
S12 TI antibacterial* or AB antibacterial*
S11 TI antibiotic* or AB antibiotic*
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S10 (MH “Antiinfective Agents”)
S9 (MH “Drug Therapy”)
S8 (MH “Antibiotics+”)
S7 S1 or S2 or S3 or S4 or S5 or S6
S6 TI ( aom or ome ) or AB ( aom or ome )
S5 TI middle ear inflam* or AB middle ear inflam*
S4 TI middle ear infect* or AB middle ear infect*
S3 AB glue ear* or TI glue ear*
S2 TI otitis media or AB otitis media
S1 (MH “Otitis Media+”)
Appendix 6. LILACS search strategy
> Search > (MH:“otitis media” OR “otitis media” OR “Otite Média” OR MH:C09.218.705.633$) AND (MH:“Anti-Bacterial
Agents” OR antibiotic$ OR Antibacterianos OR Antibióticos OR MH:“Drug Therapy” OR Quimioterapia OR “Terapia por Dro-
gas” OR Farmacoterapia OR MH:“Anti-Infective Agents” OR Antiinfecciosos OR MH:ampicillin OR Ampicilina OR ampicillin$
OR MH:D02.065.589.099.750.750.050$ OR MH:D02.886.108.750.750.050$ OR MH:D03.438.460.825.750.050$ OR MH:
D03.605.084.737.750.050$ OR D04.075.080.875.099.221.750.750.050$ OR MH:cephalosporins OR cephalosporin$ OR Ce-
falosporinas OR MH:D02.065.589.099.249$ OR D02.886.665.074$ OR D04.075.080.875.099.221.249$ OR MH:macrolides
OR macrolide$ OR Macrólidos OR Macrolídeos OR D02.540.505$ OR D02.540.576.500$ OR D04.345.674.500$ OR MH:
penicillins OR penicillin$ OR Penicilinas OR MH:D02.065.589.099.750$ OR D02.886.108.750$ OR D03.438.260.825$ OR
D03.605.084.737$ OR D04.075.080.875.099.221.750$ OR amoxicillin$ OR Amoxicilina OR cefdinir OR cefpodoxim$ OR ce-
furoxim$ OR azithromycin$ OR Azitromicina OR clarithromycin$ OR Claritromicina OR erythromycin OR Eritromicina) > clini-
cal˙trials
F E E D B A C K
Antibiotics for AOM, 22 November 2000
Summary
1. Types of interventions includes surgical procedures versus placebo which are not dealt with in this review and should therefore be
deleted.
2. The authors included only six studies in the analysis but in 1994 another meta-analysis by Rosenfeld and colleagues to which the
authors refer was published which included 33 randomized trials with 5400 children. Were any studies with a no-treatment control
excluded and if so why?
3. The meta-analysis by Rosenfeld is only mentioned in the text; there is no reference to it. How many patients were included in the
meta-analysis?
4. It is stated that trials analysed on an intention to treat basis were preferred. This indicates that other trials were excluded which does
not seem reasonable?
5. The description of the factorial trial is unclear; I suppose the authors excluded all patients who were randomised to myringotomy?
6. In the trial by Laxdal the control group was more closely monitored. The trial therefore violates the principle that all other Traitement
etc. should be the same in the two randomised groups and it should therefore be excluded.
7. The strategy described by Dickersin lacks a publication year and it is not cited in the references.
8. The search was done in August 1994 and the Cochrane review was published in April 1997. The search should therefore have been
updated before publication since Cochrane reviews are meant to be up-to-date.
9. There is no information whether the original authors and the pharmaceutical industry were contacted about additional data including
unpublished trials and trials not registered in Medline. Useful trial data might be expected to be available in books published in
connection with symposia arranged by the drug industry for example.
10. What is quality methodology?
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11. The term blinded randomisation should be avoided since it may be confused with blinded treatments; the term concealed allocation
should be used.
12. The elaborated quality assessment scale for the trials does not appear under Results and should therefore be deleted.
13. The authors refer to Rosenfeld’s meta-analysis when they state that 80% of the children have recovered spontaneously after 24
hours. Since such a percentage refers to untreated patients it raises the question why the authors did not use their own data? If these
data are used in a meta-analysis of the risk difference the NNTB will be 23 not 12 as stated in the Cochrane review.
14. For several of the excluded studies the authors gave no reason for the exclusion.
15. There should be a cross-reference to the authors’ nearly identical review in the BMJ (24 May 1997).
Reply
The changes made were:
1. We updated the search. (see Johansen criticism 7 & 8). No recent trials were found but we recognised that the Appelman trial
qualifies (originally we had thought this was only prevention of recurrent otitis, rather than treatment of acute otitis in children with a
recurrent episode).
2. We have corrected and updated the Relative Risk Reduction and consequent Number-Needed-to-Treat (see Johansen criticism 13).
3. We have separate the four arms of the Van Buchem factorial trial, and treated this as “two” trials (i.e., two separate strata): (a) without
myringotomy - antibiotics versus placebo (b) with myringotomy - antibiotics versus placebo. (see Johansen criticism 5)
4. As suggested by Andrew Herxheimer, we have added several references including (a) Chris Cates BMJ, and (b) Kozrskyj’s meta-
analysis of short versus long duration of antibiotics (rather than just the de Saintonge paper).
5. We have made small text changes in response to Johansen’s criticisms 5 (description added), 7 (dropped), 10 (- methodological
quality), 11 (- allocation concealment), 13 (corrected in text), 14 (exclusions explained), and 15 (reference added).
6. As we have pointed out to Johansen in the BMJ correspondence, and point out in the discussion here, the Rosenfeld meta-analysis
is largely concerned with comparison between antibiotics. (see Johansen criticism 2 & 3).
Contributors
Helle Krogh Johansen
Peter C. Gøtzsche
Antibiotic versus placebo for acute otitis media, 22 November 2010
Summary
This excellent and important review was completed in 1996, and I hope it will soon be updated. It is especially worth noting and
discussing the new study by Christopher Cates (BMJ 13 March 1999, p715-6), who has successfully tried a method in his general
practice of substantially reducing the use of antibiotic in children with acute otitis media. This would considerably strengthen the
’implications for practice’ in the conclusion.
I would like to suggest that in updating this review the objectives be amended and the trial by Chaput de Saintonge et al be added,
because it contributes an important piece of evidence about the duration of amoxicillin therapy. The review concludes that some
children will benefit from antibiotic treatment, and it would be valuable to say (as a result of the Chaput trial) that the evidence
indicates that a 3-day course is no less effective than a 10-day course.
Reply
Chris and I have revised the acute otitis media review. We have made a number of modest changes, though none of these change
the conclusions. However, because a new trial is included we’ve called it a “substantive update”.
Contributors
Andrew Herxheimer
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Antibiotic versus placebo for acute otitis media, 22 November 2000
Summary
1. I am glad to see this has been updated but the text does not explain what was updated, forcing the reader who wants to know to
compare the previous version with the new one. Is it the sentence referring to Cates 99 [in implics for practice] or other points as
well?
2. There are embarrassingly many typos in the refs to excluded and additional studies: Chaput de SaintoNGE, amoxyciillin, author
not in bold in the first few additional refs, below that several authors’ names begin in lower case when they should all begin with a
capital.
3. It is implied that no comcrit was received before the final submission date for CL99 issue 3. Is this true? I think I sent one early
this year.
CONFLICT OF INTEREST: None.
Reply
Excluded and additional references have been corrected and completed.
Contributors
Andrew Herxheimer
Antibiotic versus placebo for acute otitis media, 22 June 2000
Summary
1. The new study also reported diarrhoea and rashes. Shouldn’t it be included in this outcome (side effects) also?
2. I think the methods used for calculating the NNTB should be made explicit.
3. The new trial is important because it looks at a sub-group who were believed to be a greater risk of poor outcomes. In EBM OM
Rosenfeld and Bluestone review the study inclusion criteria and state that the meta-analysis ’most likely can be applied to children 2
years of age or older with non severe AOM, and most likely cannot be applied to infants with severe symptoms’. This study provides
the best evidence that the conclusions of the meta-analysis do appear to apply to this group. Perhaps this point needs to be emphasised
(the peak incidence of AOM is 9 months).
4. I think the comment that 80% resolve spontaneously within 2 to 7 days is now slightly misleading as about 70% of the control
children were clinical failures in this new study.
5. The entry in the table ’characteristics of included studies’ should be consistent with previous entries.
6. Some typographical errors and inconsistent spelling.
Reply
Thank you for your comments and suggestions.
The Absolute risk difference was used to calculate the NNTB in this systematic review. This has now been stated in the Results
section of the review. A comment regarding the application of the conclusions to infants with severe symptoms has been added to the
discussion section. The 70% incidence of clinical failure in the Damoiseaux, 2000 study have been included and typographical errors
and inconsistencies have been corrected.
Contributors
Peter Morris
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Antibiotics for acute otitis media, 19 February 2002
Summary
The second graph (comparison of outcome Abnormal Tympanometry) has wrong labels on the X-axis.
It says ’antibiotics better’ (left) and ’placebo worse’ (right). The second should probably be ’placebo better’.
The other graphs are correctly labelled.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my
criticisms.
Reply
The label on the x-axis has been corrected and now reads ’Placebo better’.
Contributors
Johannes C van der Wouden
Antibiotics reduce the risk of mastoiditis?, 26 August 2002
Summary
I agree with other commentators that this is a very good and important review. However, I would like some more clarity concerning
one statement in your conclusions: Antibiotic treatment may play an important role in reducing the risk of mastoiditis in populations
where it is more common.
What is the basis for this statement? In the included studies with more than 2000 children only one mastoiditis case occurred in a
patient in a penicillin treated group. In the review you mention two articles concerning the mastoiditis. Firstly, the study of Rudberg
(1954), which was excluded since it was not properly randomised. Even if it were, the rate of 17 % of mastoiditis cases is in these times
highly unlikely, as is shown in the included studies. The second article by Berman (1995) is a literature review, where only the available
literature concerning developing countries were reviewed. The goal of this review was to determine the extent to which otitis media
impacts mortality and morbidity in developing countries, not to study the effect of antibiotics on (acute) otitis media or mastoiditis.
In neither of these studies evidence is shown that antibiotic treatment reduces the risk of mastoiditis, certainly not in developed
countries. Since I think the rest of the review is excellent, I wonder if you could explain to me the reasons for including this statement
in the conclusions.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
Dear Markus,
We included the caveat about mastoiditis because we, and the reviewers, were concerned about misinterpretation of the results in
situations with high rates of mastoiditis. We were mindful that “an absence of evidence is not equal to evidence of absence”. Since the
trials we analysed did not include high rates of mastoiditis, we can use them as the sole basis. Given that we have two weaker pieces of
evidence:
1. The trials do show a modest reduction in other infective complications
2. The excluded Rudberg trial did show dramatic effects that we don’t think explicable from the potential biases of that study.
Prudence would then suggest that antibiotics are advisable if there is a substantial risk of mastoiditis,
Regards,
Paul Glasziou
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
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Contributors
Markus Oei (ENT surgeon)
Incorrect NNTB, 19 June 2005
Summary
I am a bit troubled by the way the conclusions of this review are written. By combining results of treatment at Days 2 to 7 in arriving
at a NNTB of 15 one is going to underestimate treatment benefit after 2 days. In your abstract though you say the ARR is 7% and
NNTB 15 for some pain after two days. This is simply not correct. If one carefully looks at trials that record pain at the end of day 2
the ARR is in fact 20% giving a NNTB of 5. Clearly acute otitis media is an acute condition and the main benefit of antibiotics is pain
control and symptom relief. If this is measured at the end of 2 days the benefits are greater than one would surmise just from reading
the review. It would be absurd to do a review of pain relief for biliary colic treated with pethidine and measuring the outcome 7 days
later. For acute conditions symptom control in the first few days should be the outcome of interest. NNTB are meaningless unless
giving a time period at which they apply. I think the review needs correcting. This is not just of academic interest but of direct relevance
to parents and doctors faced with a child with AOM in pain. Unfortunately your review gets quoted uncritically and invariably the
NNTB of 15 is given for symptom control after 2 days. I am currently trying to correct a brochure produced here in New Zealand
for GPs to give to parents of children with AOM and it uncritically repeats this misleading information. If you want to comment on
symptom control after Day 2 DO NOT pool it with data from Day 7 or later!
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
Thank you for your comment. We agree that we should be clearer about the time frame to which the ARR 7% and NNTB 15 applies.
With the availability of results of the individual patient data meta-analysis (Rovers 2006) we are able to obtain a clearer indication of
the recovery pattern over time. We have reported this in the text and included an extra figure.
Contributors
Paul Corwin
Comment on two of the meta-analyses, 9 June 2007
Summary
Summary
Feedback: This is a comment on two of the meta-analyses in the Cochrane Review, Glasziou et al. (2004). These analyses are for the
outcomes “Vomiting, Diarrhea or Rash” and “Contralateral AOM.”
1) Vomiting, Diarrhea or Rash
First we consider the meta-analysis relating possible adverse effects of treatment. In Glasziou et al. (2004), this is done using the
composite outcome “Vomiting, Diarrhea or Rash.” The data used for this meta-analysis are reproduced in the table below.
Outcome: Vomiting, Diarrhea or Rash
Study Treatment Control
Thalin et al. (1985) 1/159 1/158
Burke et al. (1991) 53/114 36/116
Mygind et al. (1981) 3/72 1/77
Damoiseaux et al. (2000) 20 12
We noted five major problems with this meta-analysis. The first relates to clinical heterogeneity. This was manifested in variations in
terms of the types of adverse effects recorded, who recorded them (parent or physician) and the time period over which they were
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recorded (from 3-4 days to 21 days). In Thalin et al. (1985), the effects were recorded by an ENT physician on days 3-4 or days 8-10.
In Burke et al. (1991), they were recorded by a parent in a 21-day diary. In Mygind et al. (1981), it was done with 7 day parental score
card. And in Damoiseaux et al. (2000), this was done by a physician on day 4 and day 11.
Another related problem is the use of the outcome “Vomiting, Diarrhea or Rash” as an entity. Vomiting is only reported in Burke et
al. (1991). It is not clear whether it was not observed, or observed but not reported in the other studies. Also, in Burkeat al. (1991),
as noted, such effects were recorded over a 21-day period while the maximum recording period for the other studies was 11 days. The
totals then gave a much higher weight to Burke et al. (1991) than may be appropriate.
A third problem is possible double or triple counting with the use of the composite outcome. For Burke et al. (1991), the group
numerator is the sum of the cases for each effect. A number of children may well have had two or three of these effects at the same time.
A fourth problem is also with the numbers used. Damoiseaux et al. (2000) gives two sets of numbers for “de novo diarrhoea,” for day
4 and for day 11. Glasziou et al. (2004) uses the day 4 numbers only. The reason for this choice is not clear. It may be better to use the
sums of the numbers for the two days (provided this does not involve double counting.)
Further, the group denominators used for Burke et al. (1991) are perhaps not what they should be. In this study, the adverse effects
were recorded by parents. Only 220 (treatment = 107, control = 113) out of a total of 232 (treatment = 114, control = 118) diaries
were collected. Using the total group size in the numerator (also done in Burke at al. (1991)) is thus not appropriate.
Finally, it is not clear if the numbers for adverse effects in Burke et al. (1991) and Damoiseaux et al. (2000) included the cases known
or suspected to have dropped out of the study due to an adverse effect.
In our view, this meta-analysis should be modified as follows: First, do not use the data on vomiting until it is reported in at least one
other study. Second, do not use a composite adverse effect outcome. Instead, perform separate meta-analyses for diarrhoea and rash.
Third, for Damoiseaux et al. (2000), use the total numbers for day 4 and day 11, with the above noted qualification in mind. Fourth,
for Burke et al. (1991) change the denominators as noted above. Finally, include drop outs due to side effects in the meta-analyses. The
table below gives the possible numerators to be used for these meta-analysis.
Separated Data on Side Effects
Vomiting Diarrhea Rash
Study T C T C T C
Thalin et al. (1985) ? ? 0 0 1 1
Burke et al. (1991)+ 20 14 24 16 16 9
Mygind et al. (1981) ? ? 2 1 1/2? 0
Damoiseaux et al. (2000)*,+ ? ? 20 12 0 3
Damoiseaux et al. (2000)? ? ? 34 22 0 3
Note: ? Unclear if vomiting not observed or not reported.
Note: ? = 2 if a dropout was not counted; else = 1.
* Day 4; ? Day 4 and Day 11; + unclear if dropouts counted.
2) Contralateral AOM
The occurrence of contralateral AOM, as is made clear in Glasziou et al. (2004), is relevant for only the cases with unilateral AOM at
the outset. This numbers in the table below are used for the meta-analysis of this outcome in Glasziou et al. (2004).
Outcome: Contralateral AOM
Study Treatment Control
Thalin et al. (1985) 4/159 17/158
Burke et al. (1991) 29/98 33/102
Mygind et al. (1981) 2/72 6/77
Overall 35/329 56/337
The first problem is clinical heterogeneity, as noted in the table below. The issues in that respect are similar to those stated for the meta-
analysis of adverse effect.
Clinical Heterogeneity: Contralateral AOM
Study Time Period Evaluator(s)
Thalin et al. (1985) day 8-10 or day 30 ENT Physician
Burke et al. (1991) 21 days Parent
Mygind et al. (1981) 1 week Physician
A further problem with this meta-analysis is the denominators used. Consider this issue for each study.
Thalin et al. (1985): The denominators in Glasziou et al. (2004) include unilateral and bilateral cases. Only 82% of the episodes were
unilateral at the start but the breakdown by group is not given in the paper. We obtained adjusted denominators as follows. Treatment:
0.82?159 = 130; Control: 0.82?158 = 130. The bias now remains the same but the precision level is now corrected.
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Burke et al. (1991): The denominators represent the total unilateral cases for each group. The study authors used these denominators.
Completed 21-day diaries, the source of data on contralateral otitis, were, however, available only for 107 (of 114) in the treatment
group and 113 (of 118) in the control group. So either one assumes that only the bilateral cases had missing diaries (which is unlikely)
or that the rate of missingness in each group was not affected by laterality. In the latter case, the adjusted denominators are: Treatment:
(98?107)/114 = 92; Control: (102?113)/118 = 98. The level of bias remains unknown but the precision level is possibly better.
Mygind et al. (1991): The denominators used include unilateral and bilateral cases. But there were 8 bilateral cases in the placebo
group and 14 in the control group. So the appropriate denominators are Treatment: 72 - 8 = 64; Control: 77 - 14 = 65. The bias and
precision levels are now corrected.
The appropriately adjusted data for this meta analysis are given below.
Contralateral AOM: Adjusted Data
Study Treatment Control
Thalin et al. (1985) 4/130 17/130
Burke et al. (1991) 29/92 33/98
Mygind et al. (1981) 2/64 6/65
Overall 35/286 56/294
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Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
1) We acknowledge the variation in methods of collecting and recording information on adverse events and in the types of adverse
events reported in the included trials. We contend however, that considering vomiting, diarrhoea or rash as an entity is justified by the
easier interpretation it provides. Though the events are biologically very different, they are of similar seriousness; irritating and difficult
to manage but minor in nature. Also, as pointed out in the above comments, dividing the adverse events into each type would not be
helpful as they are infrequently reported (i.e. vomiting is only reported in one study). We recognise that ’lumping’ the adverse events
together is a crude approach but believe the benefits in continuing to do so outweigh the drawbacks. In the discussion section of this
update we have made reference to the results of the individual patient data meta analysis (Rovers 2006) (which included a subset [n =
6 ] of the trials included in this review [n = 10]) which reports separately on the frequency of diarrhoea and rash in the treatment and
control groups. We appreciate your consideration and suggestions related to the inclusion of drop outs due to side effects in the Burke
and Damoiseaux studies. Corrections to the data have been incorporated.
2) Thank you for pointing out the numerical errors in the meta analysis of contralateral AOM. We have corrected the analysis as
suggested. This results in a minor changed to the pooled random effects OR (OR 0.44 95% CI 0.16, 1.26 versus 0.45 95% CI 0.16,
1.23) with antibiotics appearing to reduce contralateral AOM though the effect was not significant with the random effects model.
Contributors
Karim F. Hirji, D.Sc
Peter C. Gøtzsche
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Antibiotics for acute otitis media in children, 8 March 2011
Summary
The title and conclusion of the review need revising as it is just reviewing the effect of penicillin family antibiotic on the AOM and
not other antibiotics. It is suggesting to changed the title to “Usage of penicillin family Antibiotics for acute otitis media in children”.
Warm regards.
PS: The only included trials were too old and they just used the publish data:
Halsted 1968 ampicillin 100 mg/kg/day or phenethicillin 30 mg/kg/day plus sulphisoxazole 150 mg/kg/day
Howie 1973 one of erythromycin, ampicillin, or triple sulphonamide plus erythromycin
Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization
or entity with a financial interest in the subject matter of my feedback.
Reply
The title is our intention. However, as you point out, it just so happens that most (but not all) antibiotics trialled against placebo for
acute otitis media were from the penicillin group. Moreover more trials might be undertaken using non-penicillin antibiotics. So it is
appropriate to retain the original title.
Chris Del Mar, 19 June, 2012
Contributors
Amirkambiz Hamedanizadeh, Medical Doctor
WH A T ’ S N E W
Date Event Description
26 April 2015 New citation required but conclusions have not changed The conclusions regarding the effectiveness and safety of
antibiotics have essentially not changed, except for some
new outcomes (e.g. long-term effects on AOM recur-
rences) and minor changes to the risk of bias
26 April 2015 New search has been performed We updated the searches in April 2015.
In this updated review, we now provide outcome data on:
• pain at 24 hours, two to three days, four to seven
days and 10 to 14 days (in earlier versions outcome data
on pain were presented at 24 hours, two to three days
and four to seven days);
• abnormal tympanometry findings at two to four
weeks, six to eight weeks and three months (in earlier
versions outcome data on abnormal tympanometry
findings were presented at four to six weeks and three
months);
• long-term effects including number of parent-
reported AOM-symptom episodes, antibiotic
prescriptions, health care utilisation as assessed at least
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one year after randomisation (in earlier versions no data
on long-term effects were presented).
The outcome ’Adverse effects likely to be related to the
use of antibiotics such as vomiting, diarrhoea or rash’ has
been added to primary outcomes (in earlier versions this
outcome was listed as a secondary outcome) according to
the recommendations described in Chapter 5.4.2 of the
Cochrane Handbook for Systematic Reviews of Interventions
(“the primary outcomes should include at least one de-
sirable and at least one undesirable outcome”) (Higgins
2011).
One new trial was identified for the review of antibiotics
against placebo (Tapiainen 2014). This study included
children aged between six months and 15 years and pro-
vided data on pain at days four to seven, adverse effects
likely to be related to the use of antibiotics, abnormal
tympanometry findings at two to four weeks and six to
eight weeks, tympanicmembrane perforation and serious
complications
New data were added to the review from previously in-
cluded trials
For the review of antibiotics against placebo:
• data on pain at 10 to 12 days (Hoberman 2011);
• data on abnormal tympanometry findings at two
to four weeks (Kaleida 1991);
• data on long-term effects (Burke 1991;
Damoiseaux 2000).
For the review of immediate antibiotics against expectant
observation:
• data on pain at 11 to 14 days (Spiro 2006);
• data on abnormal tympanometry findings at two
to four weeks (McCormick 2005);
• data on long-term effects (Little 2001).
We identified one ongoing trial
(ACTRN12608000424303). The objective of this dou-
ble-blind, placebo-controlled randomised clinical trial is
to assess the effectiveness of azithromycin for sevendays in
aboriginal children with asymptomatic AOM, defined as
a bulging tympanic membrane without associated symp-
toms at the time of diagnosis. The primary outcome is the
proportion of children with a bulging tympanic mem-
brane or ear discharge or withdrawn due to complications
or side effects at 14 days
Quality of evidence is now described based on the
GRADE framework
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H I S T O R Y
Protocol first published: Issue 1, 1995
Review first published: Issue 3, 1996
Date Event Description
8 November 2012 New search has been performed A new review author joined the team to update this
review. We updated the searches in November 2012.
Two new trials were identified for the review of an-
tibiotics against placebo (Hoberman 2011; Tähtinen
2011). These studies included children < 35 months
of age and provided data on pain (Tähtinen 2011),
contralateral otitis, late recurrences (Hoberman 2011)
, perforation and adverse events (Hoberman 2011;
Tähtinen 2011).
The Laxdal 1970 trial has been removed from the re-
view of antibiotics against placebo and added to the
review of immediate antibiotics versus expectant ob-
servation
No new trials were identified for the review of immedi-
ate antibiotics compared with expectant observation.
Furthermore, we did not identify ongoing trials
In this updated review, we now provide outcome data
for pain at 24 hours, two to three days and four to
seven days (in earlier versions outcome data for pain
were presented at 24 hours and two to seven days)
8 November 2012 New search has been performed The general conclusions and recommendations re-
garding the effectiveness of antibiotics on pain and ad-
verse events remained unchanged
Antibiotic treatment led to a statistically significant re-
duction of children with AOM experiencing pain at
two to seven days compared with placebo, but since
most children (82%) settle spontaneously, about 20
children must be treated to prevent one suffering from
ear pain at two to three and four to seven days. (In the
previous version the number needed to treat to benefit
(NNTB) was 16). However, in this updated review an-
tibiotic treatment appeared to have a statistically sig-
nificant beneficial effect on the number of tympanic
membrane perforations (risk ratio (RR) 0.37, 95%
confidence interval (CI) 0.18 to 0.76; NNTB 33) and
contralateral acute otitis media (AOM) episodes (RR
0.49, 95%CI 0.25 to 0.95;NNTB11) comparedwith
placebo
For every 14 children treatedwith antibiotics one child
experienced an adverse event (such as vomiting, diar-
rhoea or rash) that would not have been occurred if
antibiotics were withheld. (In the previous version the
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number needed to treat to harm (NNTH) was 24)
Antibiotics are most useful in children under two years
of age with bilateral AOM, or with both AOM and
otorrhoea. For most other children with mild disease,
an expectant observational approach seems justified.
We have no data on populations with higher risks of
complications
19 June 2012 Feedback has been incorporated Feedback added to review.
2 September 2009 Amended 95% confidence intervals corrected for the outcome
pain at two to seven days and adverse events stated in
the abstract and body of the review
2 July 2008 New search has been performed The search was updated in July 2008. Four new tri-
als were identified and included in the review (Le
Saux 2005; McCormick 2005; Neumark 2007; Spiro
2006). One of these trials compared antibiotics with
placebo (Le Saux 2005). For the outcome pain at 24
hours and two to seven days, inclusion of this trial
did not alter the overall conclusions of the primary
analysis. The three other new trials compared immedi-
ate antibiotics with various observational approaches
(McCormick 2005;Neumark 2007; Spiro 2006). One
of the new trials compared immediate antibiotics with
delayed prescribing (Spiro 2006). The other trials com-
pared immediate antibiotics with ’watchful waiting’,
in which no prescription was supplied but advice on
when to seek treatment was provided (McCormick
2005; Neumark 2007). Outcome data on pain at three
to seven days from these trials were analysed with data
from another trial of immediate versus delayed pre-
scription (Little 2001). In earlier versions of the review
data from the Little trial had been included in a sensi-
tivity analysis (Little 2001). In this update, data from
the four trials comparing immediate versus observa-
tional management strategies have been included in
the main analysis. Information on subgroups of chil-
dren who are most likely to benefit from treatment
with antibiotics, obtained from a meta-analysis of in-
dividual patient data, has been included in this re-
view (Rovers 2006). Methods of the IPD meta-analy-
sis, conducted by two authors on this review (and oth-
ers) are also included. Survival curves from the IPD
meta-analysis showing the pattern of recovery from
acute otitis media over time has been included as an
extra figure. Two ongoing trials comparing antibiotics
with placebo in children < 35 months have been iden-
tified
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17 January 2008 Amended Converted to new review format.
4 September 2007 Feedback has been incorporated Feedback added.
18 February 2005 Feedback has been incorporated Feedback and reply added.
24 March 2003 New search has been performed Searches conducted.
24 August 2002 Feedback has been incorporated Feedback added.
17 February 2002 Feedback has been incorporated Feedback added.
20 November 2000 Feedback has been incorporated Feedback comments and replies added.
3 February 2000 New search has been performed Searches conducted.
3 February 2000 New citation required and conclusions have changed Conclusions changed.
30 December 1998 New search has been performed Searches conducted.
30 July 1994 New search has been performed Searches conducted.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this 2015 updated review, we now provide outcome data on:
• pain at 24 hours, two to three days, four to seven days and 10 to 14 days (in earlier versions outcome data on pain were
presented at 24 hours, two to three days and four to seven days);
• abnormal tympanometry findings at two to four weeks, six to eight weeks and three months (in earlier versions outcome data on
abnormal tympanometry findings were presented at four to six weeks and three months);
• long-term effects including number of parent-reported AOM-symptom episodes, antibiotic prescriptions and health care
utilisation as assessed at least one year after randomisation (in earlier versions no data on long-term effects were presented).
The outcome ’Adverse effects likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash’ has been added to primary
outcomes (in earlier versions this outcome was listed as a secondary outcome) according to the recommendations described in Chapter
5.4.2 of the Cochrane Handbook for Systematic Reviews of Interventions (“the primary outcomes should include at least one desirable and
at least one undesirable outcome”) (Higgins 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Age Factors; Anti-Bacterial Agents [adverse effects; ∗therapeutic use]; Earache [drug therapy]; Otitis Media [∗drug ther-
apy; prevention & control]; Pain [drug therapy]; Randomized Controlled Trials as Topic; Secondary Prevention; Tympanic Membrane
Perforation [drug therapy]
MeSH check words
Adolescent; Child; Child, Preschool; Humans; Infant
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